Articles de revues sur le sujet « Miguel Antonio Caro »

En la historia de la crítica literaria en Colombia se ha aceptado la verdad incontrovertible de Miguel Antonio Caro como autor de las cartas, en una famosa discusión estética, donde polemiza con el crítico Baldomero Sanín Cano. El artículo pretende mostrar que Manuel Uribe Ángel fue el verdadero remitente de ellas; y trata de examinar las ideas surgidas en este debate frente al pensamiento clásico y moderno; controversia que se convierte en ejemplo de las posiciones encontradas que dominaron la reflexión literaria de finales del siglo XIX en el país.Descriptores: Sanín Cano, Baldomero; Caro, Miguel Antonio; Uribe Ángel, Manuel; Nuñez, Rafael; epistolarios; Literatura Colombiana; Siglo XIX; Cartas abierta a Brake.Abstract: In the history of Colombian literary criticism the incontrovertible truth that Miguel Antonio Caro is the author of some letters containing a famous aesthetic discussion, in which he confronts the critic Baldomero Sanín Cano has been accepted. The article tries to show that Manuel Uribe Ángel was truly the sender of those letters and tries to examine the ideas concerning the classical and modern thought appearing in this debate. This controversy becomes an example of the most common opposite positions present in the literary reflections by the end of XIX Century in Colombia. Key words: Sanín Cano, Baldomero; Caro, Miguel Antonio; Uribe Ángel, Manuel; Nuñez, Rafael; Collected letters; Colombian literature; XIX Century; Cartas abiertas a Brake.

Este artículo se concentra en la obra latina de Miguel Antonio Caro. Para comenzar, se trata la enseñanza del latín en la Colonia y las reformas educativas de finales del siglo XVIII y comienzo de la época republicana,las cuales promovieron la enseñanza de la ciencia moderna, sin la supresión absoluta de las humanidades. A continuación, se aborda la figura de Caro, reconstruyendo aspectos de su biografía y, particularmente, de su formación autodidacta. Se resaltan las contribuciones conceptuales y metodológicas de la Gramática latina escrita en colaboración con R. J. Cuervo y se brinda un panorama detallado de su producción literaria: sus traducciones de autores clásicos, entre ellos, Virgilio, Horacio y Tibulo; sus traducciones de poetas modernos y contemporáneos, como Fray Luis de León o A. Manzoni; y, finalmente, su propia obra poética.

Este artículo propone una presentación de las ideas más distintivas de la concepción estética y literaria en Miguel Antonio Caro. Muestra que sus argumentos se encuentran fuertemente permeados por elementos religiosos, morales y políticos que desvirtúan la naturaleza, realidad y dignidad del quehacer poético. Para este propósito revisaremos los temas principales que en materia de estética y literatura fueron abordados por el autor colombiano: el origen de la poesía y el fenómeno creativo artístico, los criterios de lo que es digno y censurable de la poesía, el estudio de los modelos clásicos, la interpretación de la idealidad artística, al igual que la relación entre ciencia y poesía. Finalmente, expondremos las razones por las cuales la postura de Caro representó uno de los más fuertes obstáculos para la instauración de la modernidad estética en Colombia.

<p>El artículo analiza la concepción de Miguel Antonio Caro en torno a la ciencia. En el primer apartado se reseñan las críticas del pensador bogotano contra la filosofía positivista, que en sus tres versiones (el positivismo de Comte, el evolucionismo biológico de Darwin y el evolucionismo social de Spencer) pretende poner las hipótesis científicas por encima de las verdades de la religión. A continuación, se expone la doctrina católica del autor en torno al verdadero saber científico, que en coincidencia con Meléndez Pelayo, Caro estima necesariamente afín a la fe. Para concluir, se discute la visión reaccionaria de Caro sobre la ciencia moderna, ya que ésta ha estado en la base de la mentalidad anticientífica de la educación en Colombia.</p>

<p>El artículo analiza la concepción de Miguel Antonio Caro en torno a la ciencia. En el primer apartado se reseñan las críticas del pensador bogotano contra la filosofía positivista, que en sus tres versiones (el positivismo de Comte, el evolucionismo biológico de Darwin y el evolucionismo social de Spencer) pretende poner las hipótesis científicas por encima de las verdades de la religión. A continuación, se expone la doctrina católica del autor en torno al verdadero saber científico, que en coincidencia con Meléndez Pelayo, Caro estima necesariamente afín a la fe. Para concluir, se discute la visión reaccionaria de Caro sobre la ciencia moderna, ya que ésta ha estado en la base de la mentalidad anticientífica de la educación en Colombia.</p>

El presente artículo aborda los entendimientos que Miguel Antonio Caro esgrimió acerca del concepto de moral. Este fue un eje central dentro de su lenguaje y constituyó una parte fundamental de los lineamientos ideológicos que propiciaron la transformación administrativa y política del Estado en el último cuarto del siglo xix en Colombia. Sobre esta premisa, el propósito del artículo es brindar un análisis sobre la propuesta de moralización de la sociedad elaborada por Caro, la cual no solo abarcó política, religión y educación, sino que también promovió un marco conductual para la sociedad. La consolidación de esta propuesta, expresada en la Constitución política de 1886, permite comprender, en perspectiva, el periodo histórico conocido como la Regeneración.

This paper highlights a unique phenomenon in Colombia, the entanglement between Latin and power, epitomised by the pivotal role of President and Latinist Miguel Antonio Caro. The study of Classics arrived in the territory with the first conquerors from Spain at the end of the 16th century and Caro stands on the shoulders of a long Classical tradition in New Granada. A member of the Conservative Party and a humanist, he was widely known for his work and contribution in the Political Constitution of the Republic of Colombia of 1886 and his central role in the formation of the modern state of Colombia. Besides politics, Caro co-authored a Latin Grammar, wrote many articles on translation and Latin Literature, composed poetry in Spanish and Latin, and produced the first translation of the complete works of Vergil in Spanish. Caro’s works and days aptly demonstrate the association between grammar, Classics, and state power throughout the history of Colombia. The paper contextualises the role of Classics from the colonial period until the end of the 19th century and sketches Caro as an individual and a politician. It outlines his scholarly activity, which involved grammar, translation, and scholarly publishing, and underlines his influence on other scholars and his idiosyncratic interest as a decisive political figure in re-invigorating interest in Latin language and literature.

Este trabajo se concentra en Antonio José Restrepo y Miguel Antonio Caro, dos figuras del liberalismo y conservadurismo colombiano y también poetas-traductores, que publicaron sus versiones de poemas franceses en el fin del siglo XIX, en Poesías originales y traducciones poéticas (1899) y Traducciones poéticas (1889). El análisis de algunas de sus estrategias de traducción permite poner de relieve el uso diferente que tienen de la poesía francesa, abriendo así una pista de reflexión sobre el papel político de la traducción durante la Hegemonía Conservadora.

"Este libro es resultado del proyecto “Política e intelectuales: la imagen de España en el siglo XIX”. La investigación general fue financiada por la Fundación Carolina y la Universidad de Antioquia, y se centró en el estudio de la recepción de España, como referente ideológico, en la obra y el pensamiento de tres intelectuales hispanoamericanos del siglo XIX, a saber: Andrés Bello, Manuel González Prada y Miguel Antonio Caro."

Parte de la tradición crítica ha tendido a estudiar la obra de Miguel Antonio Caro separando su pensamiento en dos líneas distintas: el político, por un lado, y su tarea como humanista, por otro. El presente artículo se propone analizar su labor de crítico literario y de traductor como parte fundamental de su proyecto político: el de diseñar y consolidar un proyecto de nación colombiana. El objetivo, pues, consiste en evitar la división mencionada, que, como propongo, ha obstaculizado la comprensión de su proyecto de nación como un todo, en el que las discusiones políticas y las reflexiones sobre literatura nacional e incorporación de otras literaturas son esenciales.

este texto se propone analizar las imágenes de las cuatro musas de la portada de la revista El Montañés (1897) revisando, en primer lugar, su consideración como musas de acuerdo con fuentes clásicas e iconográficas, luego aborda el contexto intelectual de la publicación periódica, en especial la “estética gramaticalista” de Miguel Antonio Caro, la preocupación por la consolidación de la literatura antioqueña y la relevancia de Tomás Carrasquilla. Se descubre dos comprensiones de la figura de las musas: una gramaticalista y otra montañesa, vinculadas a dos maneras de comprender la literatura en el contexto cultural del siglo XIX.

Este libro se ocupa de la configuración de la ciencia del lenguaje en Colombia desde 1867 —año atado a las reformas educativas de los gobiernos del Olimpo radical y en el que se publicó la primera edición de la Gramática de la lengua latina de Miguel Antonio Caro y Rufino José Cuervo— hasta 1911 —fecha del deceso de Cuervo; Caro había muerto en 1909—. Al insistir en el proceso productivo de la forma vernácula de un conocimiento técnico con pretensiones universales, evita hacer énfasis en lo que se haya recibido de tradiciones intelectuales foráneas o valorar esa recepción en los términos del centro y la periferia. Así, el principal valor del libro es que se concentra en la circulación de un saber y los efectos de ese movimiento sobre el modo de ser de ese saber circulante.

Aquí se tratará de analizar críticamente algunos de los más fundantes elementos constitutivos del discurso político de Miguel Antonio Caro sobre lo político. Plantearemos en este texto algunos elementos centrales de la pretensión de Caro de redefinir un juego de relaciones de poder a partir de ese mismo juego de relaciones de poder, entendiendo la suya como una propuesta que desde la hegemonía -desde la oposición o desde el control del Estado- pretendió y consiguió elaborar una redefinición absoluta del poder/contrapoder: es decir, estatuir una definición "necesaria" de la relación política y su implementación en una estructura institucional Estatal que la materializara; consiguiendo postular en su discurso, y parcialmente en la estructura jurídico-institucional colombiana que contribuyó a diseñar y poner en juego, como perteneciente a “la naturaleza de las cosas”, la propia posición que legitimaba y definía al Estado, en tanto “nacional”, como “naturaleza Donde el contenido de “lo nacional” se identificaba con la noción de “patria”, y "la patria” representaba la puesta en escena de su estrategia de "ontologizar" el orden social.

El autor ofrece su comprensión sobre las implicaciones sociales y culturales del denominado Grecolatinismo o Grecoquimbayismo como expresión artística y política que, por comodidad y acaso por desconocimiento de algunos de sus intérpretes, suele circunscribirse sólo al ámbito del Gran Caldas y en especial a un grupo de escritores e intelectuales de Manizales, entre ellos Aquilino y Silvio Villegas, Guillermo Alzate Avendaño y Fernando Londoño. El propósito es debatir lo grecoquimbaya o grecolatino, que más allá del sentido irónico que envuelve ambas expresiones –utilizadas por escritores influyentes capitalinos, miembros del Grupo de Barranquilla y simpatizantes del Nadaísmo–, toca una forma de la cultura colombiana y hace visible la complejidad de unas tradiciones literarias en las que tienen lugar las disímiles expresiones artísticas de Miguel Antonio Caro, José Asunción Silva, Guillermo Valencia, José Eustasio Rivera y León de Greiff.Palabras clave: grecolatinismo, “grecoquimbayismo”, Gran Caldas, sociedad, cultura, Silvio Villegas, literatura, “Leopardos”.Intellectual and political views of GrecoquimbayismoAbstract The author offers his understanding about the social and cultural implications of so-called Greco-Latin or Grecoquimbayismo as an artistic and political expression, that for convenience and may be ignorance of some of its interprets, it is usually restricted only within the Gran Caldas and in particular to a writers and intellectuals group from Manizales, among them Aquilino and Silvio Villegas, Guillermo Alzate Avendaño and Fernando Londoño. The purpose is to discuss about Grecoquimbaya or Greco-Latin, that beyond the ironic sense that both terms imply - used by influential writers from the Capital, members of the Barranquilla Group and Nadaism followers - , touches a pattern of Colombian culture and makes visible the literary traditions complexity in which take place the different artistic expressions from Miguel Antonio Caro, José Asunción Silva, Guillermo Valencia, José Eustasio Rivera and Leon de Greiff. Keywords: Greco-Latin, "grecoquimbayismo" Gran Caldas, society, culture, Silvio Villegas, literature, "Leopardos"

Esta investigación-acción, se fundamentó en el propósito de fortalecer el pensamiento espacial-geométrico a través de las inteligencias múltiples, en estudiantes de educación infantil, en el colegio Miguel Antonio Caro IED, de Bogotá, entre los años académicos 2014 y 2018 respectivamente. La presente, se enmarcó en un enfoque mixto, de tipo descriptivo, en una población de escolares, de educación básica primaria, de grados tercero y quinto. La recolección de información se basó en la técnica de observación directa, en conjunción con los resultados logrados por los educandos, en las pruebas estatales SABER primaria y datos obtenidos con la aplicación del cuestionario del profesor, para diagnosticar inteligencias múltiples en primaria de Armstrong (2001); y la adaptación de Prieto y Ballester (2003). Estimados los datos perfilados, se concluyó, en la necesidad de mediar académicamente, por medio del diseño y ejecución de un programa de intervención pedagógica, estructurado con estrategias dinamizadas, desde las inteligencias múltiples, conducentes al afianzamiento del pensamiento espacial-geométrico, en los colegiales, lográndose potenciar habilidades y competencias matemáticas, propias del pensamiento espacial-geométrico.

La vida de Cervantes es un rosario de contratiempos, adversidades, vejámenes y sufrimientos. Miguel conoció la pobreza desde la cuna y la vida errante hasta la muerte.Apenas tocado por el hálito del prestigio literario en su juventud, habiendo escrito algunas poesías con motivo del fallecimiento de Ia tercera esposa del rey Felipe II, Isabel de Valois, por encargo de su maestro López de Hoyos quien lo Ilamó »mi caro y amado discípulo«, se vio envuelto en un duelo con un tal Antonio de Sigura, andante en la Corte, al cual había inferido varias heridas, según parece, por razones de honor. Este desafortunado suceso tuvo por consecuencia una cédula real que lo condenaba en rebeldía a que »eon vergüenza pública le fuese cortada Ia mano derecha- la mano de la pluma y la espada! -y a diez anos de destierro.« Pero, como no hay mal que por bien no venga, Cervantes huyó a Italia cuyo arte y cultura renacentistas lo fascinaron, salvando así su integridad física del bárbara fallo. En Roma entro en el servicio del cardenal Acquaviva en calida.d decamarero.

La vida de Cervantes es un rosario de contratiempos, adversidades, vejámenes y sufrimientos. Miguel conoció la pobreza desde la cuna y la vida errante hasta la muerte.Apenas tocado por el hálito del prestigio literario en su juventud, habiendo escrito algunas poesías con motivo del fallecimiento de Ia tercera esposa del rey Felipe II, Isabel de Valois, por encargo de su maestro López de Hoyos quien lo Ilamó »mi caro y amado discípulo«, se vio envuelto en un duelo con un tal Antonio de Sigura, andante en la Corte, al cual había inferido varias heridas, según parece, por razones de honor. Este desafortunado suceso tuvo por consecuencia una cédula real que lo condenaba en rebeldía a que »eon vergüenza pública le fuese cortada Ia mano derecha- la mano de la pluma y la espada! -y a diez anos de destierro.« Pero, como no hay mal que por bien no venga, Cervantes huyó a Italia cuyo arte y cultura renacentistas lo fascinaron, salvando así su integridad física del bárbara fallo. En Roma entro en el servicio del cardenal Acquaviva en calida.d decamarero.

Esta investigación tiene como propósito analizar el rol que tienen las emociones en el conflicto escolar en un contexto de postconflicto en Colombia, a partir de las narraciones de los actores educativos. Para el desarrollo de este escrito, se identificaron las situaciones que generan conflicto en el escenario escolar, se estableció la frecuencia que tienen los conflictos, se analizó el papel que tienen las emociones en la generación y en la superación de los conflictos que se presentan en el escenario escolar, se estudiaron las narraciones que hacen los actores educativos de la forma como las emociones intervienen en las situaciones de conflicto y se estableció la incidencia del conflicto escolar en el contexto de postconflicto que vive Colombia actualmente. El estudio se llevó a cabo en el Colegio Miguel Antonio Caro de Engativá y buscó establecer el tipo de situaciones que conducen a la generación de conflicto, la existencia de normas relacionadas con la convivencia y manejo de conflictos en la institución, la agresividad en los conflictos escolares, las formas de superación del conflicto, el nivel de preparación de la institución para superar conflictos, las emociones observadas, las personas emocionalmente involucradas, los hechos generadores de emociones, así como las emociones presentes durante la convivencia pacífica.

El siguiente artículo da cuenta de los resultados obtenidos de la aplicación de una evaluación diagnóstica sobre reproducción celular en estudiantes de grado séptimo, octavo y noveno de los colegios Miguel Antonio Caro IED y Justo Víctor Charry IED, jornada tarde. El manejo de estos conceptos es primordial para que los estudiantes lleguen a comprender otras temáticas importantes dentro de la biología como lo son la genética, al entender los procesos de transmisión de caracteres hereditarios; la evolución de los seres vivos desde la variabilidad, la selección natural y la preservación de las especies; y en la biología del desarrollo, al reconocer la mitosis como proceso para la formación de un nuevo ser a partir de divisiones sucesivas de las células; entre otros. Este es un trabajo de investigación mixta, a través de la aplicación de un cuestionario con preguntas de selección múltiple con única respuesta, acompañado de una entrevista. El análisis de resultados se realizó con relación a número de aciertos, porcentajes de acierto, porcentajes de selección de respuesta y competencias desarrolladas, lo que permitió identificar las bases conceptuales y/o dificultades de los estudiantes frente a la comprensión y aprendizaje de los conceptos relacionados con la reproducción celular, y las falencias en cuanto al desarrollo de competencias en ciencias naturales que le permitan a los estudiantes conocer y actuar con relación a su entorno. Así mismo, se sugiere la planeación y diseño de una estrategia de enseñanza-aprendizaje-evaluación, la cual tome en cuenta las características y necesidades de la población a la que va dirigida, y decida sobre los contenidos a incluir.

Book reviews - Crítica de libros - Crítica de livros Markus Lampe & Paul Sharp: A Land of Milk & Butter. How Elites Created the Modern Dairy Industry Carin Martiin Christopher Dyer, Erik Thoen and Tom Williamson: Peasants and their fields. The rationale of open-field agriculture, c. 700-1800 José Luis Martínez-González Juan Antonio Quirós Castillo (Ed.): Archaeology and History of Peasantries 1. From the Late Prehistory to the Middle Ages. Guillermo García-Contreras Ruiz Dietmar Müller: Bodeneigentum und Nation. Rumänien, Jugolawien und Polen im europäischen Vergleich Miguel Cabo Villaverde Fernando Collantes y Vicente Pinilla: ¿Lugares que no importan? La despoblación de la España rural desde 1900 hasta el presente Javier Esparcia Francesc Valls Junyent: La Catalunya atlántica. Aguardiente y tejidos en el arranque industrial catalán Llorenç Ferrer-Alòs Elena Catalán Martínez, Gabriel Jover Avellà y Enrique Llopis Agelán (Eds.): El delme com a font per a la història rural Pegerto Saavedra Jaume Torras Elias: Canvis i conflictes en el món rural català (segles xviii-xix). Onze estudis d’història econòmica i social Jesús Millán García-Varela Miguel Ángel del Arco Blanco (Ed.): Los «años del hambre». Historia y memoria de la posguerra franquista José Miguel Martínez Carrión Fernando Collantes: ¿Capitalismo coordinado o monstruo de Frankenstein? La Política Agraria Común y el modelo europeo, 1962-2020 Alicia Langreo Navarro Sergio Molina García: Una llave para Europa. El debate agrario franco-español y la adhesión de España a la CEE (1975-1982) Rafael Castro

La casa número 21 de la calle Mariblanca, el proyecto de Miguel Fisac para el instituto Nuestra Señora de la Victoria, los retablos de la Catedral, la plaza del Siglo, el Corralón de la Aurora, la composición abstracta en dos planos de Dámaso Ruano para la plaza del Niño de las Moras, la casa palacio de la Familia Gálvez, la arquitectura de la Acera de la Marina, la casa n.º 5 de la calle Sagasta, el mercado de Atarazanas, la arquitectura de González Edo para el restaurante Antonio Martín, el Matadero Municipal, los jardines de la Hacienda del Retiro, el proyecto del Edificio Horizonte… Sin lugar a dudas, la guía histórico-artística que dirigió la profesora Rosario Camacho en 1992 fue y es un instrumento indispensable para comprender por qué la mayor parte de estos espacios hoy son lugares de Málaga, en suma, la imagen patrimonio-cultural que ofrece la ciudad de Málaga. La Guía históricoartística es un instrumento en la praxis del patrimonio cultural.

Book reviews Dulce Freire and Pedro Lains (Eds.). An Agrarian History of Portugal, 1000-2000: Economic Development on the European Frontier. Leiden/Boston, Brill, 2017, 347 pp. Benedita Câmara Annie Antoine (Ed.). Agricultural Specialisation and Rural Patterns of Development. Turnhout, Brepols, 2016, 303 pp. Piet van Cruyningen Guido Alfani and Cormac Ó Gráda (Eds.). Famine in European History. Cambridge, Cambridge University Press, 2017, 325 pp. Xavier Cussó Segura Marc Badia-Miró, Vicente Pinilla and Henry Willebald (Eds.). Natural Resources and Economic Growth: Learning from History. Abingdon/New York, Routledge, 2015, 374 pp. Sara Torregrosa Hetland Niccolò Mignemi. Coopératives et mondes agricoles: France et Italie (1880-1950). Rennes, Presses Universitaires de Rennes, 2017, 337 pp. Miguel Cabo Domingo Gallego, Luis Germán y Vicente Pinilla (Eds.). Estudios sobre el desarrollo económico español. Dedicados al profesor Eloy Fernández Clemente. Zaragoza, Prensas de la Universidad de Zaragoza, 2016, 408 pp. Santiago M. López-García Ricard Garcia Orallo. La terra a subhasta. Crisi, endeutament i despossessió al món rural català de finals del segle xix. Barcelona, Publicacions de l’Abadia de Montserrat, 2015, 644 pp. Samuel Garrido Lluís Serrano Jiménez. Tancar la terra: Pràctiques de propietat i dinàmiques socials (Catalunya, 1850-1910). Girona, Documenta Universitaria/Associació d’Història Rural de les Comarques Gironines, 2016, 324 pp. Antonio Miguel Linares Luján Jordi Planas Maresma. Francesc Torras Sayol (1868-1936): Un propietari conservador al capdavant de l’acció cooperativa. Barcelona/Valls, Fundació Roca i Galès/Cossetània Edicions, 2016, 102 pp. Josep M. Pons-Altés Josep Joan Mateu González. Enginyers i regants: El Canal d’Aragó i Catalunya (1896-1940). Lleida, Universitat de Lleida/Patronat Josep Lladonosa, 2017, 256 pp. Carles Sanchis Ibor Gladys Karina Sánchez Juárez. Los pequeños cafeticultores de Chiapas: Organización y resistencia frente al mercado. Tuxtla Gutiérrez, CESMECA-UNICACH, 2015, 225 pp. Albert Folch David Sowell. Medicine on the Periphery: Public Health in Yucatán, Mexico, 1870-1960. Lanham, Lexington Books, 2015, 205 pp. Mikel Astrain Pablo Alonso González. El Antipatrimonio: Fetichismo y dominación en Maragatería. Madrid, Centro Superior de Investigaciones Científicas, 2017, 326 pp. Guadalupe Jiménez Esquinas Marcel Mazoyer y Laurence Roudart. Historia de las agriculturas del mundo: Del Neolítico a la crisis contemporánea . Oviedo, KRK, 2016, 1.073 pp. Cristóbal Gómez Benito

Abstract Background: The current first-line (1L) standard of care (SOC) for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) is trastuzumab (T) plus pertuzumab (P) and a taxane. Despite advances in 1L SOC, most patients (pts) progress during maintenance therapy with T+P. Tucatinib is a tyrosine kinase inhibitor (TKI) approved in combination with T and capecitabine for adults with HER2+ MBC, with and without brain metastases (BM). In HER2CLIMB, the addition of tucatinib significantly prolonged progression-free survival (PFS) and overall survival (OS) in pts with HER2+ MBC and was well tolerated. Adding tucatinib also reduced the risk of disease progression or death in pts with untreated and/or active BM (Murthy et al. 2020, Curigliano et al. 2021). HER2CLIMB-05 investigates whether adding tucatinib to 1L SOC as maintenance therapy will extend PFS while maintaining quality of life (QOL). Methods: HER2CLIMB-05 (NCT05132582) is a phase 3, randomized, double-blind study evaluating tucatinib plus T+P as maintenance therapy for HER2+ MBC. Approximately 650 pts will be enrolled. Eligible pts will have advanced HER2+ disease, no progression on 4–8 cycles of prior 1L SOC, ECOG Performance Status of 0 or 1, and no or asymptomatic BM. Exclusion criteria include prior treatment with anti-HER2 and/or anti-epidermal growth factor receptor TKI (prior SOC for early BC is permitted) or inability to undergo contrast magnetic resonance imaging of the brain. Pts will be randomized 1:1 to receive either tucatinib or placebo twice daily, with T+P once every 21 days. Pts with HR+ disease may receive endocrine therapy. The primary endpoint is investigator-assessed PFS. Secondary endpoints include OS (key endpoint), time to deterioration of health-related QOL, central nervous system PFS, safety, and pharmacokinetic (PK) parameters. PFS and OS will be compared using a 2-sided stratified log-rank test between treatment groups. Time-to-event endpoints will be summarized using the Kaplan–Meier method. PK and safety data will be summarized using descriptive statistics. Enrollment is ongoing in the US, with additional sites planned. Citation Format: Erika Hamilton, Junji Tsurutani, Giuseppe Curigliano, Miguel Martín, Ciara C. O’Sullivan, Joo Hyuk Sohn, Konstantinos Tryfonidis, Libero Santarpia, Shan Yang, Véronique Diéras. Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT2-16-03.

Reseñas Bibliográficas correspondientes al número 10 de Barataria. Para visualizar/descargar la reseña correspondiente diríjase al apartado texto completo (pdf). ÍNDICE de las reseñas: Autor: A. Martín Cabello, pp. 225-226 Texto: Paul BOGHOSSIAN El miedo al conocimiento. Contra el relativismo y el constructivismo Madrid: Alianza. 2009, [2006].187 pp. Autora: M.I. Morán Morán, pp. 226-228 Texto: Francisco MARCOS-MARÍN y Amando DE MIGUEL Se habla español Madrid: Biblioteca Nueva. 2009. 279 pp. Autor: E. Díaz Cano, pp. 228-229 Texto: Lorenzo CACHÓN RODRÍGUEZ La España «inmigrante»: marco discriminatorio, mercado de trabajo y políticas de integración Barcelona: Anthropos. 2009. 351 pp. Autor: G. Tardivo, pp. 229-231 Texto: Roland TERBORG y Laura G. GARCÍA LANDA (Coords.) Los retos de la planificación del lenguaje México: UNAM - México. 2006. 2 vols. 630 pp. Autora: A. García Manso, pp. 231-232 Texto: María GÓMEZ ESCARDA e Isidro SEPÚLVEDA MUÑOZ (Eds.) Las mujeres militares en España Madrid: Instituto Universitario General Gutiérrez Mellado. 2009. 322 pp. Autor: E. Díaz Cano, pp. 233-234 Texto: Antonio MARTÍN CABELLO Perspectivas teóricas en torno a la sociología de la cultura Madrid: Dykinson S.L. 2009. 134 pp. Autora: A. García Manso, p. 234 Texto: Juan MAESTRE ALFONSO Guatemala. Entre volcanes y poetas Córdoba: Almuzara, Colección Sotavento. 2008. 192 pp. Autor: G. Tardivo, pp. 234-235 Texto: Abel HERNÁNDEZ Historias de la Alcarama Madrid: Gadir. 2008. 244 p. Autora: M. I. Morán Morán, pp. 236-237 Texto: Ángel VALERO LUMBRERAS El giro político de la epistemología Madrid: Biblioteca Nueva. 2008. 316 pp. Autor: E. Díaz Cano, pp. 238-239 Texto: Vicente J. BENITO GIL, José M. CANALES ALIENDE y María Erley ORJUELA RAMÍREZ (Coords.) Estado del bienestar y políticas sociales: una aproximación a la situación española y colombiana Alicante: Editorial Club Universitario. 2008. 294 pp. Autor: F. Ruiz de Pablos, pp. 239-241 Texto: Maximiliano FERNÁNDEZ FERNÁNDEZ Larra, en las elecciones de 1836, cómplices y adversarios Segovia: Junta de Castilla y León. 2009. 231 pp.

Abstract Genetic testing for cancer susceptibility is a cornerstone of precision cancer prevention and care. Major communication hurdles remain for the differently specialized professionals involved in the identification, counselling, and clinical management of at-risk individuals. This may be ascribed to gaps in the genetic/genomic literacy of health care providers and to an ambiguous lexicon used for variant description. The Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) international consortium endorses controlled terminology and a framework for interpretation and reporting of germline variants in cancer susceptibility genes (PMID: 30962250). However, for most ENIGMA affiliates a language other than English is used for written and verbal communication of genetic test results, potentially confounding local application of the published framework. The ENIGMA Clinical Working Group thus launched a Vocabulary Translation Project (VTP) to translate the ENIGMA recommendations into the various languages spoken by the membership. The VTP involved 65 ENIGMA members from 22 countries organized into 19 language-specific teams, covering Catalan, Chinese, Czech, Danish, Dutch, Finnish, French, Galician, German, Greek, Italian, Japanese, Malay, Norwegian, Polish, Portuguese, Spanish (Castilian), Swedish, and Tagalog. Excerpts from the original publication were selected for translation based on a majority consensus and included a glossary of terms and recommendations for interpreting and reporting germline sequence variants in (breast) cancer susceptibility genes. Using a two-step process, each team conducted the relevant translation followed by independent back-translation to English. The VTP proved useful to reappraise the reference text. It disclosed transnational issues, which prompted revision of the original source to emphasize that risk estimates and actionability were based on breast cancer as an exemplar. It also highlighted country-specific differences with regards to breast cancer risk assessment (e.g. different absolute/relative breast cancer risk cut points) and management. As a secondary outcome, via electronic survey of the participating teams we documented the perceived high value of the translation effort and its expected positive impact on more consistent clinical management of carrier individuals. The identified target audience encompasses medical geneticists, physicians of other specialties participating in multidisciplinary teams, genetic counselors, primary care physicians, as well as non-health care professionals, e.g. journalists and science communicators. The outreach program includes dissemination of the translations via local, regional, and especially national networks and their use for education and training purposes. Because French, Portuguese, and Spanish are widely used as official, co-official, or secondary languages, the reach of the VTP potentially extends to a greater number of countries and territories, mostly in Central and South America, Caribbean, and Africa. By moving a step forward towards terminological coherence across disciplines and borders, we will facilitate more precise delivery and clinical application of genetic test results for breast cancer predisposition. Our translated recommendations will improve interdisciplinary cross-talk and carriers’ awareness of the risks and implications associated with their status, contributing to more informed decision-making. We used breast cancer as a blueprint. Application of the model to other cancer types will require calibration on the cancer-specific absolute and relative risks. Citation Format: Arcangela De Nicolo, Diana M. Eccles, Sarah Louise Ariansen, Michela Biancolella, Miguel de la Hoya, Orland Diez, Hans Ehrencrona, Florentia Fostira, Tiara Hassan, Issei Imoto, Artur Kowalik, Fabienne Lesueur, Arjen R. Mensenkamp, Heli Nevanlinna, Joanne Ngeow, Edenir I. Palmero, Inge Søkilde Pedersen, Frances Que, Jana Soukupová, Yen Tan, Ana Vega, Amanda B. Spurdle, Paolo Radice. Don’t get lost in translation: Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) recommendations for reporting germline cancer susceptibility gene variants in 19 languages – breast cancer as a model [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-02-15.

Abstract Background Advances in the multidisciplinary care of hormone-receptor positive (HR+) early breast cancer (eBC) have markedly improved clinical outcomes: however, disease recurrence may still occur, particularly in patients (pts) with moderate or high-risk cancers at the time of diagnosis. The use of CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) is a standard of care for advanced breast cancer, supporting the rationale to study CDK4/6i in the eBC setting. Here we present the final protocol-planned analyses of the global phase III PALLAS trial investigating whether the addition of the CDK4/6i palbociclib (P) to adjuvant ET improves outcomes over ET alone for HR+/HER2- eBC. Methods PALLAS (PALbociclib CoLlaborative Adjuvant Study, NCT02513394) is a randomized phase III open-label trial in which pts with stage II-III HR+/HER2- eBC were randomized to receive either 2 years of P with adjuvant ET (P+ET) or ET alone. The primary endpoint is invasive disease-free survival (iDFS); secondary endpoints include distant recurrence-free survival (DRFS), locoregional recurrence-free survival (LRRFS), overall survival (OS), and safety. Mandatory biospecimen collection has supported the creation of an expansive translational science program, and long-term follow-up is planned. Revised sample size calculations required recruitment of 5600 pts in order to detect a 25% iDFS improvement in patients receiving P+ET with 85% power; this final protocol-planned analysis was planned after 469 iDFS events. Results From September 1, 2015 to November 30, 2018, 5,761 pts (median age 52 years, range 22-90) were randomized in 406 centers in 21 countries worldwide. 1,014 (17.6%) had stage IIA disease (capped) and 4,728 (82.1%) stages IIB/III. 4,754 (82.5%) had received prior (neo)adjuvant chemotherapy. After a protocol-planned 2nd interim analysis in May 2020 crossed the futility threshold, 349 P+ET pts still on active treatment stopped P and were transferred to follow-up. At the time of final analysis cutoff date (November 20, 2020), after a median follow-up of 31 months and 516 events recorded, iDFS was similar between the two arms, with 3-year iDFS of 89.3% (95% CI: 87.8-90.6%) for Palbo+ET, and 89.4% (88.0-90.7%) for ET alone (hazard ratio 0.96, 95% CI: 0.81-1.14). There was no statistically significant difference in secondary outcome endpoints. Subgroup analyses revealed no significant interactions between treatment effect and other factors (including risk category). The safety profile of P was as expected, with grade 3 or 4 neutropenia the most common side effect (safety population: 1759/2841 [61.9%] vs 11/2902 [0.4%]). Overall 42% of pts. discontinued P prior to the planned 2-year duration, 28.2% of Palbo+ET pts discontinued therapy due to adverse events, without an observed impact on survival outcomes. Conclusions Now with the full number of events, this analysis of the PALLAS trial shows that the addition of 2 years of P to ongoing adjuvant ET did not improve survival endpoints for pts with stage II-III HR+/HER2- eBC. Whether P is beneficial in the adjuvant setting for certain sub-groups of pts will be further evaluated with longer-term follow-up and by the ongoing translational science program. Support: ABCSG; AFT; Pfizer; ClinicalTrials.gov Identifier: NCT02513394; https://www.abcsg.org; https://acknowledgments.alliancefound.org Citation Format: Michael Gnant, Amylou C Dueck, Sophie Frantal, Miguel Martin, Hal Burstein, Richard Greil, Peter Fox, Antonio C Wolff, Arlene Chan, Eric Winer, Christian Singer, Kathy Miller, Marco Colleoni, Michelle Naughton, Gabor Rubovszky, Judith Bliss, Ingrid A Mayer, Guenther G Steger, Zbigniew Nowecki, Olwen Hahn, Norman Wolmark, Hope Rugo, Georg Pfeiler, Hannes Fohler, Otto Metzger, Céline Schurmans, Kathy P Theall, Dongrui R Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele*, Erica L Mayer, *shared last authorship. Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS1-07.

Abstract Aberrant splicing is a major hallmark of cancer, affecting tumor progression, metastasis, and therapy resistance. The oncogenic activity of specific cis splicing errors and trans-acting splicing factor misregulation in patient tumors have been demonstrated in multiple studies. As such, cancer-associated splicing dysregulation is a novel source of clinically actionable biomarkers and therapeutic targets, particularly for the treatment of insensitive cancers such as Triple Negative Breast Cancer (TNBC). Envisagenics’ SpliceCore technology is an innovative cloud-based software platform that integrates machine learning (ML) algorithms with high performance computing to analyze large RNA-seq datasets to predict biologically relevant, novel, and highly prevalent tumor specific alternative splicing (AS) changes. Using SpliceCore, we have analyzed &gt;2500 RNAseq samples from different breast cancer subtypes as well as normal breast tissue and identified several AS targets with the potential to translate into therapeutic candidates for TNBC. Interestingly, one of our leading AS targets is an exon skipping isoform that is present in 60.5% of TNBC patients and correlates with poor overall survival, without showing differences in gene expression between all the breast cancer subtypes and healthy patients studied. In addition, SpliceCore was used to predict and design a set of splice switching oligos (SSO) that can efficiently switch the skipping isoform to an inclusion isoform in TNBC cells. The skipping isoform plays a critical role in tumor progression via a TGFβ-dependent mechanism as demonstrated by detailed isoform switching studies using SSO-0205. Pretreatment of the TNBC cells with SSO-0205 24 hours before TGFβ pathway activation modulated TGFβ pathway related protein levels and cellular localization and reversed the cell proliferative response associated with it. This resulted in a strong inhibition of p21 gene expression, accompanied by a 50% decrease on the number of cells in G2, the mitotic phase of the cell cycle, and 40% decrease on cell viability. Additionally, migratory response induced by TGFβ in TNBC cells was also significantly inhibited by SSO-0205 pretreatment, which downregulated ANGPTL4 gene expression followed by a 55% decrease in cell migration. In summary, we were able to uncover a novel therapeutic target for TNBC, whose aberrant splicing contributes to TNBC pathogenesis by promoting an overactivation of the TGFβ pathway. Our results provide experimental proof of concept that demonstrate SpliceCore’s ability to discover novel disease specific AS targets and design splice correcting oligonucleotides for subsequent therapeutic development. Reversal of this aberrant TNBC specific splicing using SSOs represent a new and promising therapeutic approach that will have a significant impact on TNBC treatment and clinical care. Moreover, SpliceCore can be applied to multiple other indications opening a new avenue for therapeutic development in cancer. Citation Format: Miguel A Manzanares, Priyanka Dhingra, Kendall Anderson, Vanessa Frederick, Adam Geier, Alyssa Casill, Martin Akerman, Gayatri Arun. Novel therapeutic target for triple negative breast cancer uncovered by SpliceCore® an innovative platform that identifies disease-specific alternative splicing [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-17-11.

Abstract Patients with triple negative breast cancer (TNBC), who have co-morbid type 2 diabetes (T2D), have higher risk for metastatic disease and cancer-related mortality. Adipose tissue in T2D is inflamed/dysfunctional and secretes factors that reprogram breast tumor cells. However, adipocyte crosstalk with breast cancer cells is not well understood. Preliminary data suggest this crosstalk promotes immune exhaustion in the tumor microenvironment. It is well established that patients with chronic T2D are ‘immune exhausted’, exhibiting impaired metabolism, reduced effector function, and elevated expression of immune checkpoint proteins on multiple T cell subsets in the periphery and tumor infiltrates. We hypothesized that dysfunctional adipose tissue drives this immune exhaustion in the breast microenvironment, through exosome communication. Recent studies have focused attention on exosomes, which are membrane-enclosed extracellular vesicles (EVs) that contain parent cell-specific biomolecules on the membrane and in the cargo, which are delivered to recipient cells. We tested EVs purified from conditioned media of insulin resistant (IR), primary mature breast adipocytes for their ability to upregulate PD-L1 expression in MDA231 and MCF7 cells, as models of TNBC and ER+ breast cancer. We compared to EVs purified from conditioned media of insulin sensitive (IS), primary mature breast adipocytes as controls. Adipose tissue was obtained surgically with consent from reduction mammaplasty patients without known breast cancer. IR adipocyte EVs upregulated PD-L1 mRNA and protein expression in both cell types, and five times more than IS adipocyte EVs in MCF7 cells. Our laboratory has proven that BET bromodomain proteins regulate transcription of several immune check point genes in TNBC. We found that BET protein inhibition by the pan-BET inhibitor JQ1, and the BRD4-selective PROTAC degrader MZ1, disrupts exosome-driven PD-L1 expression. Network analysis of the exosome-mediated signaling suggests that regulation of immune exhaustion ligands is coupled to epithelial-to-mesenchymal transition and metastatic potential. Understanding the effect of metabolically abnormal breast adipocytes in patients with breast cancer and T2D will help refine prognosis, evaluate responses to immune checkpoint therapies such as atezolizumab, which is approved for PD-L1 positive TNBC, and potentially prevent tumor metastasis. To our knowledge, our study is the first to test the impact of exosomes derived from primary mature breast adipocytes, as a function of insulin sensitivity and patient metabolism, on immune exhaustion in invasive breast cancer. Our findings inform clinical considerations and follow up of breast cancer patients with T2D. These refinements are critical because, at present, breast adipocyte health does not inform the standard of care in breast medical oncology. Our insights should improve treatment for immune dysfunction in T2D cancer patients at risk for tumor progression. 424 words3,004 characters with spaces Citation Format: Naser Jafari, Manohar Kolla, Isabella Pompa, Tova Meshulam, Miguel Batista Junior, Gerald V Denis. Exosomes from primary breast adipocytes induce immune exhaustion in triple negative breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-04-08.

Abstract Background: Adjuvant ET has been the standard of care for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) EBC. A significant proportion of patients with increased risk still experience disease relapse despite available ET and more optimum ET is needed to prevent patients developing incurable metastatic cancer. Distant recurrence risk ranges from 20% to 40% after 5 years of adjuvant ET, depending on clinicopathological (clin-path) features at diagnosis. Consequently, there is a need to further optimize adjuvant treatment, particularly in those patients who are at increased risk of recurrence. Imlunestrant is an orally bioavailable selective estrogen receptor degrader (SERD) with pure antagonistic properties and the potential to overcome ET resistance. In early phase trials, imlunestrant monotherapy showed favorable safety with pharmacokinetic (PK) exposures exceeding fulvestrant and preliminary efficacy in ER+, HER2- advanced breast cancer patients (EMBER, Jhaveri 2022) along with robust biological/pharmacodynamic activity and tolerability in EBC (EMBER-2, Neven). Trial Design: EMBER-4 is a randomized, open-label, global phase 3 study comparing imlunestrant versus physicians’ choice of ET, in patients who are at an increased risk of recurrence based on clin-path features and who have received 2 to 5 years of standard adjuvant ET. Approximately 6,000 patients will be randomized 1:1 to receive imlunestrant (400 mg daily) for 5 years or physicians’ choice of adjuvant ET (tamoxifen or an aromatase inhibitor, AI, dosed per label). Study treatment duration is 5 years. Males and pre-/peri-menopausal women will receive concomitant treatment with a GnRH agonist if receiving imlunestrant or an AI. Stratification factors include time from initial adjuvant ET, use of prior adjuvant cyclin dependent kinase 4/6 inhibitors, nodal status, menopausal status, and geographic region. Eligibility criteria: Eligible patients are adult males and females (pre-, peri- or postmenopausal) with ER+, HER2- EBC who have completed definitive locoregional therapy and have received 2 to 5 years of prior adjuvant ET without disease recurrence, but who are at increased risk of recurrence based on clin-path features at diagnosis. Prior (neo) adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor is permitted. Study endpoints: The primary endpoint is invasive disease-free survival (IDFS), excluding second non-breast primary invasive cancers. Key secondary endpoints include distant relapse-free survival, overall survival, IDFS including second non-breast primary invasive cancers, safety, PK and patient reported outcomes. Recruitment for EMBER-4 begins globally in Q4 2022. Citation Format: Komal Jhaveri, Joyce O’Shaughnessy, Fabrice Andre, Matthew P. Goetz, Nadia Harbeck, Miguel Martín, Francois-Clement Bidard, Zachary M. Thomas, Suzanne Young, Roohi Ismail-Khan, Lillian M. Smyth, Michael Gnant. EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT1-01-02.

La publicación XXVIII, número 2, de revista Persona y Sociedad, al igual que los números anteriores, concentra estudios e investigaciones sobre las siguientes disciplinas de las ciencias sociales: filosofía política, teoría sociológica, sociología política, ciencia política, vinculadas a casos correspondientes de la sociedad civil y a la construcción e implementación legislativa. Esta edición tiene un especial contenido sobre las realidades sociales y políticas de la región latinoamericana, siempre enfrentada a procesos de transformación y ajustes en el nuevo escenario de la 'sociedad mundial'. El primer artículo que abre esta publicación es de Felipe Mansilla, cuyo título es "La naturaleza conservadora de las concepciones antioccidentalistas. Observaciones incómodas sobre un tema actual". Para este análisis, el Tercer Mundo -y en especial mención la región latinoamericana- es el propósito de este ensayo, que indaga sobre el impacto y la divulgación que han tenido las ideas de pensadores como Walter Benjamin y Carl Schmitt entre los adherentes de las doctrinas de la subalternidad y la descolonización en el continente latinoamericano. El segundo artículo de esta publicación analiza el actual posicionamiento teórico de Habermas en relación con su reconocimiento del importante lugar que ocupa la religión en el espacio público-político. Su autor, Santiago Prono, considera que este espacio de modelación tiene consecuencias incluso en el concepto mismo de sociedad civil, logrando la participación de ciudadanos religiosos en el marco conceptual de la política deliberativa. Miriam Kriger y Juan Dukuen encabezan la tercera investigación, en la cual estudian las disposiciones políticas de jóvenes estudiantes argentinos de clase alta de Buenos Aires durante los años 2011 y 2013. La estructura de este análisis se basa en la perspectiva bourdieuana en diálogo con la psicología cultural, cuyo foco es el estudio de la intervención del pensamiento político y el juicio moral en la formación de disposiciones políticas de este grupo social. En cuarto lugar, el artículo "Bolivia: lucha indígena hacia las autonomías", de María Fernanda Herrera, realiza un análisis crítico del presente boliviano con respecto a la consecución de derechos y autonomías territoriales. Aun cuando el año 2009 fue un momento clave para la articulación de movimientos sociales y originarios en dicho país, al punto de llegar a establecer un Estado plurinacional, la Nueva Constitución limita su construcción debido a las normativas institucionales de la misma. Finalmente, la publicación de Lucía Salazar titulada "Reconociendo el feminicidio. La exigencia en sociedad y la legislación ecuatoriana", pone el acento en el último proceso legislativo que se ha llevado a cabo en Ecuador desde la aprobación del Código Integral Penal. Desde una visión crítica, la autora considera los debates existentes en legisladores, jurisconsultos y en la sociedad ecuatoriana en general. Este número cuenta además con dos breves reseñas. En primer lugar, Ceferino Muñoz reseña La persona humana y su formación en Antonio Millán-Puelles, de Mauricio Bicocca, cuyo eje principal aborda la formación individual y social de la persona humana. La segunda reseña la realiza Miguel González Vallejos sobre el texto Indagación cristiana en los márgenes. Un clamor latinoamericano, con prólogo de Antonio Bentué, de Diego lrarrázaval. Aquí el autor invita a reflexionar sobre la siguiente premisa: "el acontecer ordinario y el contacto entre personas y culturas diferentes permiten descubrir voces y silencios de Dios. Esto conlleva tomar distancia de idolatrías contemporáneas".

Abstract Background: Gedatolisib is a potent reversible dual inhibitor that selectively targets all Class I isoforms of phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). Two separate pivotal clinical trials demonstrated that PI3K and mTOR inhibitors are active in combination with endocrine therapy and prolong progression-free survival (PFS) among patients with hormone receptor positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) who had previously received endocrine therapy (SOLAR-1, BOLERO-2). CDK4/6 inhibitor (CDK4/6i) therapy has been approved in the front-line setting. However, patients eventually experience disease progression on CDK4/6i based therapy. Available data indicates that resistance to CDK4/6i is a transient adaptive mechanism that may be reversed by adding inhibitors of the PI3K/mTOR pathway (PI3K/mTORi). Thus, combination of PI3K/mTORi and CDK4/6i in patients whose disease progressed on prior CDK4/6i could potentially both restore sensitivity to CDK4/6i and prevent adaptive activation of the PI3K/mTOR pathway. This hypothesis was evaluated in a Phase 1b study (Layman SABCS 2021). Subjects with HR+/HER2- ABC who were CDK4/6i pretreated received gedatolisib (180 mg IV weekly for 3 weeks, then one week off) in combination with standard doses of palbociclib and fulvestrant. Median PFS was 12.9 months, and overall response rate was 63%. Grade 3-4 adverse events (AE) were observed at a low rate, and toxicity was overall easily managed with available standards of care, and few patients discontinued treatment due to treatment-related adverse events (4%). The most common AE was stomatitis; hyperglycemia of any grade occurred in 26% of patients. This preliminary data, dosing schedule, and study population characteristics form the basis for the Phase 3 trial, VIKTORIA-1. Trial design: This Phase 3, open-label, randomized, multinational two-part clinical trial will evaluate the efficacy and safety of gedatolisib and fulvestrant with or without palbociclib in patients with HR+/HER2- ABC previously treated with any CDK4/6i in combination with non-steroidal aromatase inhibitor therapy. Those without tumor PIK3CA mutations will be assigned to Study 1 and those with PIK3CA mutations will be assigned to Study 2. Study 1 will include up to 351 subjects randomized in a 1:1:1 ratio to Arm A (gedatolisib, palbociclib, and fulvestrant), Arm B (gedatolisib plus fulvestrant), or Arm C (fulvestrant). For subjects in Arm C whose disease progresses, crossover to Arm A or B is allowed. Study 2 will include up to 350 subjects randomized in a 3:3:1 ratio to Arm D (gedatolisib, palbociclib, and fulvestrant), Arm E (alpelisib plus fulvestrant), or Arm F (gedatolisib plus fulvestrant). Key eligibility criteria include adults with confirmed metastatic or locally advanced breast cancer, any menopausal status for females, radiologically evaluable disease, and prior CDK4/6i treatment with non-steroidal AI. Prior therapy with SERD, including fulvestrant is allowed. Key exclusion criteria include prior treatment with a PI3K, protein kinase B (Akt), or mTOR inhibitor, prior treatment with chemotherapy for advanced disease, more than two lines of prior endocrine therapy, bone only disease with no soft tissue components, active CNS metastases, and type 1 diabetes or uncontrolled type 2 diabetes. The primary endpoint is PFS assessed by blinded independent central review (BICR) per RECIST v1.1. Secondary endpoints included overall survival (OS), safety and tolerability, ORR, duration of response, time to response, CBR, quality of life, and pharmacokinetics. This trial is open for enrollment. Citation Format: Sara Hurvitz, Fabrice Andre, Massimo Cristofanilli, Giuseppe Curigliano, Antonio Giordano, Hyo S. Han, Miguel Martín, Barbara Pistilli, Hope Rugo, Robert Wesolowski, Samuel Suzuki, Sarah C. Mutka, Igor Gorbatchevsky, Sibylle Loibl. A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT3-26-02.

Abstract Background. Standard-of-care treatment for HER2-positive metastatic breast cancer (HER2+ mBC) patients has traditionally included targeted therapies such as trastuzumab and/or pertuzumab in first line (1L) and ado-trastuzumab emtansine (T-DM1) in the second line (2L). In 2021, fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu®) was approved following DESTINY-Breast 03 trial results, demonstrating a significant reduction in the risk of progression compared to T-DM1 in 2L. Contemporary data on treatment patterns and clinical outcomes for HER2+ mBC patients after their 1L therapy in a real-world setting is limited and would help understand whether all eligible patients receive optimal and timely targeted therapies. This study aimed to report 2L treatment patterns and outcomes among HER2+ mBC patients in the United States (US). Methods. Adult HER2+ mBC patients with ≥2 lines of therapy were identified from the Syapse Learning Health Network (LHN) database; a longitudinal US oncology database integrating data from community health systems, labs and other external sources. Included patients initiated 2L treatment for metastatic disease between January 2014-February 2021 (index date), allowing for 12-months of follow-up. Descriptive statistics for patient characteristics, treatment patterns including prior metastatic treatments, time to treatment discontinuation (TTD), and reasons for 2L discontinuation were reported. Results. Of the 15,241 breast cancer patients in the LHN with abstracted data, 312 HER2+ mBC patients received ≥2L treatment. The patients were mostly White (69%) or African American (21%), median age of 59 years (interquartile range [IQR], 50-66) at start of 2L. The African American population was typically diagnosed young (median age 50 [IQR, 44-61] vs. 54 [IQR, 46-62] years) with stage IV disease at initial diagnosis (69% vs 62%) versus Whites. Majority of the 312 patients had stage IV disease at initial diagnosis (62%); most common sites of metastasis at mBC diagnosis were bone (52%), distant lymph node(s) (38%), liver (36%) and brain (10%). The median length of follow-up was 22 months (IQR, 13-37), 54% had initiated their 2L therapy since 2018. Majority of the 312 patients had received a trastuzumab-based (T-based) regimen in 1L (78%). Among the 312 patients, 37% had received only 2 lines of therapy in the metastatic setting, 28% received 3 and 35% received ≥4 lines of therapy. In 2L, 89% of the 312 patients received a HER2-targeted treatment (monotherapy or combination); the most frequent 2L regimens included T-DM1 monotherapy (29%), trastuzumab/pertuzumab/taxane (10%) and T-DM1/trastuzumab (8%). Subsequently, 197 of the 312 patients (63%) received 3L therapy. Among these 197 patients, T-DM1 monotherapy (19%), T-DXd monotherapy (10%) and capecitabine/lapatinib (8%) were the most frequently reported 3L regimens. Around 88% (n=274) of the 312 patients discontinued their 2L therapy. Median TTD of 2L from index date was 7.2 months (95% CI, 6.5-8.9); median TTD was 10.6 months (95% CI, 7.4-14.0) among a sub-group of patients who received a T-based regimen in their 2L (N=116). Approximately 47% of patients discontinued their 2L regimen due to progression/worsening of cancer, 17% discontinued from intolerance/toxicity in the absence of progression. Conclusions. This study suggests the treatment trajectory of US HER2+ mBC patients is variable in the real world clinical practice. Approximately two-thirds of the 2L patients had to receive a subsequent therapy and disease progression was the most common reason for 2L treatment discontinuation, reflecting a remaining need to improve outcomes for patients in 2L HER2+ disease. Citation Format: Della Varghese, Giovanna I. Cruz, Colden Johanson, Liz Toland, Miguel Miranda, Eleanor C. Faherty, David Harland, Henry G. Kaplan. A real-world evidence study of treatment patterns in patients with HER2-positive metastatic breast cancer who have received at least 2-lines of therapy [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P1-11-19.

Abstract Background: SV-BR-1-GM is an irradiated allogeneic cell line derived from a hormone receptor-negative (HR-) HER2-positive (HER2+) breast cancer (BC), now engineered to express HLA class I and II antigens, secrete GM-CSF and function as an antigen-presenting cell. Here we report post-hoc exploratory data for metastatic BC (MBC) patients treated with the SV-BR-1-GM regimen (SV) alone (NCT03066947) and in combination (CO) with immune checkpoint inhibitors (ICIs) (NCT03328026). Methods: SV includes cyclophosphamide 300 mg/m2 i.v. 48-72 hours prior to SV-BR-1-GM (20 × 106 cells) intradermally followed by interferon-alpha-2b at the SV-BR-1-GM inoculation sites on days 2 and 4. SV was given every 2 weeks for 3 cycles and then monthly in NCT03066947, and every 3 weeks in combination with PD-1 inhibitors in NCT03328026. Treatment was continued until disease progression or unacceptable toxicities. Results: A total of 34 refractory MBC patients (pts) were treated, including 24 with SV, and 14 with CO, including 4 who crossed over from SV to CO plus one who restarted the SV after a protocol specified administrative interruption in treatment. Median prior regimens were 5; 55% of pts had hormone receptor-positive (HR+) BC, 42% had HER2+ BC, and 16% were triple-negative BC (TNBC). Objective response rates (ORR) were 4% for monotherapy and 7% for combination. Clinical benefit rate (CBR) was 21% for monotherapy and 29% for combination. Responses and clinical benefits were seen across most BC subtypes (see table). Notably, CBR among 10 pts with HR+ BC (any HER2) who received the combination was 50% (5/10). The duration of response (DOR) among 4 patients treated with monotherapy was 49-223 days and DOR among 6 patients treated with combination was 72-292 days. Median PFS was 2.8 months for monotherapy and 4.2 months for combination. Median OS was 7.0 months for monotherapy, and 12.0 months for combination. Of 28 pts with available prior treatment data, 12 (43%) had PFS on study treatment exceeded PFS on prior treatment, of these 8/12 had &gt;1 HLA match and 5/8 had ≥ 2 loci HLA-matched with SV-BR-1-GM. PFS ratio improvement was independent of the prior number of lines of therapy or BC subtypes. The SV-BR-1GM regimen was well tolerated with the most common treatment-related adverse events (AEs) being injection site reaction in 67%. There was no dose-limiting toxicity, special interest AEs such as cytokine storm, and no grade 5 observed. There were 2 non-treatment-related grade 4 AEs: worsening pleural effusion and altered mental status. Significant improvement in PFS was observed in patients with matched HLA and in association with the delayed-type hypersensitivity skin test, peripheral blood circulating tumor cells, and cancer-associated macrophages. Conclusions: SV-BR-1-GM demonstrated promising activity in patients with MBC. Treatment was well tolerated with no concerning AEs. The PFS ratio compares favorably with prior penultimate standards of care, more notably in patients with matched HLA. Clinical benefits were observed across multiple subtypes of BC, particularly in patients with HR+ disease receiving combination therapy. Phase II clinical trial is currently ongoing to evaluate the efficacy of SV-BR-1-GM in combination with ICIs. Clinical benefit and PFS on SV-BR-1-GM SV-BR-1-GM Whole Cell Therapeutic Vaccine in Heavily Pre-Treated Metastatic Breast Cancer Results Stratified by HER2 and HLA Matching Citation Format: Saranya Chumsri, William Williams, Mingjin Chang, Miguel Lopez-Lago, Charles Wiseman, Jarrod Holmes, Chaitali Nangia, Karim Mohammed, Minal Barve, Shaker Dakhil, Bonnie Guerin, Giuseppe Del Priore, Carmen Calfa. Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell Therapeutic Vaccine in Advanced Metastatic Breast Cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-07-12.

Abstract Background: Novel effective and safe therapies are required for advanced TNBC after progression to standard-of-care first line treatment with anti-PD-1/L1 + chemotherapy. We have found that the most aggressive TNBC variants are driven by a heterogeneous set of genetic aberrations that converge in the increased activity of 6 kinases: KIT, PNKP, PRKCE, P70S6K, ERK and CDK6 (Nat Commun; 9:3501-18). Although the inhibition of each kinase in monotherapy yielded little efficacy in preclinical models, the combinations targeting pairs of the former kinases led to therapeutic synergy in most cases. The combined inhibition of CDK6 and ERK led to 5-fold increase in overall survival in preclinical TNBC models (PDXs and spontaneous murine cancer models). The greatest activity was observed in models with increased activity of either CDK6 or ERK. Thus, we aimed to test the safety and preliminary efficacy of combined ERK and CDK6 inhibition with binimetinib and palbociclib in women with advanced TNBC with hyperactivation of ERK and/or CDK6. The combination has been preliminary tested in lung cancer, where a phase I dose-escalation trial established the RP2D in binimetinib 45 mg/BID plus Palbociclib 125 mg daily 21/7. Trial design: Single-arm, prospective, multicentric, open-label, phase IB/II trial with intra-patient dose-escalation. Patients candidate for pre-screening will have determined the activity of ERK and CDK6 with an in-house developed assay and acquisition algorithm at the central lab. Those testing positive for either marker will undergo full screening. Patients will start treatment with continuous oral binimetinib at 45 mg/BID and palbociclib 100 mg/day from days 1 to 21, in 28-day cycles. Patients experiencing ≤ grade 1 tolerable side effects as the greatest toxicity will be allowed to escalate to palbociclib to 125 in cycle 2. Fresh biopsies will be harvested at baseline and disease progression, in order to establish patient-derived organoids (PDOs) and perform WES. PBMCs will be harvested at baseline, +24 hours, and at the beginning of cycle 2, to study changes in the immunophenotype. RECIST 1.1 and NCI CTC AE V 5.0 criteria will be used for assessing disease control (q8 weeks) and toxicity. Eligibility criteria: Pre-screening: Women &gt;18 year old diagnosed of advanced, non-curable TNBC; 2) who have received a minimum of 1 treatment line including immunotherapy; 3) no more than 2 treatment lines for advanced disease; 4) Adequate organ function and recovery from previous toxicity to &lt; tolerable G2. Full screening: 5) Demonstration of hyper-activation of CDK6 and/or ERK in the tumor sample; 6) PD to the previous treatment regimen within the last 28 days. Specific aims: Primary: 1) To determine the progression-free survival time of the combination of binimetinib and palbociclib in TNBC patients with hyperactivation of ERK and/or CDK6 in second/third line 2) To assess the safety and tolerability of the former combination Secondary: 1) 6-month PFS rate, response rate, and overall survival of the combination 2) To study biomarkers of sensitivity and primary and acquired resistance to the combination taking advantage of PDOs 3) To determine the immunodynamics of the combination. Statistical methods: The null hypothesis is that the median PFS time for second/third line TNBC with best physician’s choice is 1.7 months (NEJM; 384:1529-41, 2021). With alpha and beta errors of 0.05 and 0.2, the minimum number of patients to demonstrate a 30% improvement in PFS to 2.5 months is 25. Preliminary data suggest that approximately 40% of the patients show hyper-activation of CDK6 and/or ERK; thus, and assuming a methodological failure of 10%, the minimum number of patients to screen is 69. Present accrual/target accrual: 27 screened of 69 planed; 11 accrued of 25 planned Citation Format: Luis Manso, Alfonso Cortes, Juan M Cejalvo, Serafin Morales, Jose A García Saenz, Ramon Colomer, Rodrigo Sanchez-Bayona, Jorge Silva, Juan A Guerra, Diego Malon, Silvana Mouron, Eduardo Caleiras, Miguel Quintela-Fandino. Phase IB/II trial of palbociclib and binimetinib in advanced triple-negative breast cancer with hyperactivation of ERK and/or CDK4/6 [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr OT2-19-08.

Abstract Introduction Elacestrant is the first oral, non-steroidal, selective estrogen receptor degrader (SERD) to demonstrate improved efficacy compared to standard of care endocrine treatment, with greater relative benefit in ESR1-mutated tumors, and manageable safety profile in pretreated patients with metastatic breast cancer (BC) (Bidard F.C., JCO 2022). SOLTI ELIPSE trial (NCT04797728) is a prospective, multicenter, window of opportunity trial designed to assess whether a short-course of preoperative elacestrant may suppress tumor proliferation in postmenopausal women with estrogen receptor positive (ER+)/HER2-negative early BC (Vidal M., SABCS 2021). Here, we present the results of the primary efficacy and safety study analysis. Methods Eligible patients with operable, untreated ER+/HER2-negative BC that were T1c (≥1.5 cm)-T3 by ultrasound, clinically or radiologically N0 and had a locally assessed Ki67 ≥10%, received elacestrant 400 mg once a day continuously for a total of 4 weeks. At the study treatment completion, patients were treated according to local practice. Centralized assessment of post-treatment (D28) Ki67 from surgical specimen or tumor biopsy was required for the primary endpoint evaluation. Primary efficacy endpoint was complete cell cycle arrest (CCCA), defined as Ki67≤2.7%, at D28. Ki67 geometric relative change, variation in tumor infiltrating lymphocytes (TILs), switch in PAM50 subtypes and differential expression of 192 genes from baseline (D1) to D28 was also explored. Adverse events (AEs) were graded according to CTCAE v5.0. Results Between April 2021 and February 2022, 24 patients were enrolled and 22 were evaluable for the primary endpoint. Baseline characteristics were: mean age 69 years (range 50-81); ductal histology 74%; T1c 61%; T2 39%; grade 1-2 83%; median local Ki67 20% (10-70). Baseline PAM50 subtypes distribution was: Luminal A (n=12), Luminal B (n=8), Basal-like (n=1), Normal-like (n=1). At D28, CCCA was achieved in the 27% (n=6) of the patients. Fourteen patients (64%) had D28 Ki67 ≤10%. Paired centralized Ki67 was available in 19 patients. A statistically significant 41% (95% CI, -24 to -58) Ki67 relative reduction (rr) from D1 was observed (p=0.007). CCCA rate was 31% and 17% in patients with D1 Ki67 &lt; 20% (n=13) and D1 Ki67 ≥20% (n=6), respectively. Ki67 varied consistently in both Ki67 &lt; 20% (rr=-38%; 95% CI, -16 to -60) and Ki67 ≥20% (rr=-46%; 95% CI, -20 to -72) groups. Overall, elacestrant was associated with a shift towards a more endocrine sensitive and less proliferative phenotype based on PAM50 gene signatures. CCCA occurred in 45% of Luminal A tumors, whereas no CCCA was observed among Luminal B tumors. Levels of TILs were significantly higher at D28 (mean difference, +3.73; p=0.004). Elacestrant induced high expression of immune-response genes including IGJ, GZMB, CD4, CD8a and suppressed proliferation (e.g., UBE2T, MYBL2, BIRC5, MK67) and estrogen-signaling (e.g., ESR1, PGR, CCND1, BRCA2) genes (false discovery rate 5%). These changes in gene expression were observed both in tumors with D28 Ki67≤2.7% and in those with D28 Ki67 &gt;10%. Overall, 87% of the patients reported any grade AEs. Treatment-related AE occurred in 1 patient (grade 3 cutaneous rash) and led to treatment discontinuation. Most frequently reported AEs (all grade 1) were hot flush (n=6), dyspepsia (n=2), anemia (n=2) and constipation (n=2). No serious AEs were reported. Conclusions In untreated ER+/HER2-negative early BC a short-course preoperative treatment with elacestrant was associated with relevant biological and molecular response and with manageable safety profile. Globally, these findings support further exploration of this highly potent, novel oral SERD in early BC. Citation Format: Maria Vidal, Tomás Pascual, Claudette Falato, Rodrigo Sanchez-Bayona, Montserrat Muñoz, Isaac Cerbrecos, Xavier Gonzalez-Farré, Tomás Cortadellas, Mireia Margelí, Miguel Angel Luna, Christian Siso, Kepa Amillano, Patricia Galván, Fernando Salvador, Alejandra Espinosa, Laia Paré, Esther Sanfeliu, Aleix Prat, Meritxell Bellet Ezquerra. PD13-01 Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trial [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr PD13-01.

Abstract BACKGROUND Endocrine therapy (ET) modulates estrogen synthesis and/or estrogen receptor (ER) activity and is the mainstay of ER+ breast cancer (BC) treatment. ET + a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is the standard of care in patients (pts) with ER+, HER2– metastatic BC (mBC) in the first-line setting. Fulvestrant ± a CDK4/6i, and everolimus + exemestane, are the current regimens approved for use in the second-line setting. However, therapeutic resistance to some ETs, such as aromatase inhibitors, can arise from ESR1 mutations driving estrogen-independent transcription and proliferation. Current post-CDK4/6i treatment options are suboptimal. New therapy options are therefore needed to reduce this risk and to improve outcomes, tolerability, quality of life, and adherence to treatment. Giredestrant is a highly potent, nonsteroidal oral selective ER antagonist and degrader (SERD) that achieves robust ER occupancy and is active regardless of ESR1 mutation status. While phase I SERD combination data in the post CDK4/6 setting is encouraging, there is no randomized combination data. Combining giredestrant and everolimus may potentially improve outcomes after CDK4/6is and in pts with ESR1-mutated tumors; evERA BC is investigating this combination to address the unmet need in the post-CDK4/6i setting. TRIAL DESIGN This phase III, global, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant + everolimus vs exemestane + everolimus in pts with ER+/HER2– locally advanced (LA)/mBC who had previous treatment with a CDK4/6i and ET in the LABC/mBC or adjuvant setting. Pts will be randomized to either giredestrant (30 mg) + everolimus (10 mg) by mouth (PO) every day (QD) on Days 1–28 of each 28-day cycle, or exemestane (25 mg) + everolimus (10 mg) PO QD on Days 1–28 of each 28-day cycle. Pts will receive treatment until disease progression or unacceptable toxicity. Pts will use a dexamethasone mouth rinse four times QD for 8 weeks, started concurrently with study treatment. ELIGIBILITY Female/male pts ≥18 years with ER+/HER2– LA/mBC, an Eastern Cooperative Oncology Group Performance Status of 0–1, measurable disease defined per RECIST v.1.1 (or evaluable bone metastases with at least one predominantly lytic bone lesion confirmed by computed tomography or magnetic resonance imaging), disease progression ≥6 months after initiating ET + CDK4/6i in the LABC/mBC setting (and ≥4 months on most recent ET, if ET + a CDK4/6i was not the most recent therapy received), or relapsed either while taking or within 12 months of exposure to combination adjuvant ET (≥12 months) and a CDK4/6i (≥6 months). Availability of a baseline blood sample to determine ESR1 mutation status by circulating tumor DNA assay for testing at a central laboratory. Men and pre-/perimenopausal women will receive a luteinizing hormone-releasing hormone agonist on Day 1 of each 28-day cycle. AIMS Primary endpoint: investigator-assessed progression-free survival (PFS; per RECIST v1.1). Secondary endpoints: investigator-assessed PFS in pts with detectable ESR1-mutated tumors in circulating tumor DNA at baseline; overall survival; objective response rate; duration of response; clinical benefit rate; patient-reported outcomes; safety; pharmacokinetics. STATISTICAL METHODS The primary endpoint analysis will use a stratified log-rank test at an overall 0.05 significance level (two-sided). An independent data monitoring committee will be in place for safety. ACCRUAL Target enrollment is 224 pts globally, and this study is currently recruiting. CONTACT INFORMATION For more information or to refer a patient, email global.rochegenentechtrials@roche.com or call 1-888-662-6728 (USA only). Clinicaltrials.gov number NCT05306340. Citation Format: Erica L. Mayer, Sara Tolaney, Adam M. Brufsky, William Gradishar, Komal Jhaveri, Miguel Martín, Luca Moscetti, Gregory Vidal, Patricia Cortazar, Merilin Feldman, Bann-mo Day, Hope Rugo. evERA Breast Cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2– locally advanced or metastatic breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT2-01-07.

Abstract Background Pseudomonas aeruginosa (PA) pneumonia is associated with morbidity and mortality in mechanically ventilated, intensive care unit (MV ICU) patients despite best clinical care. We assessed efficacy, PK, and safety of MEDI3902 in MV ICU subjects in the placebo-controlled, randomized Phase 2 EVADE study (NCT02696902; EudraCT 2015-001706-34). Methods Subjects with PCR-confirmed PA colonization of the lower respiratory tract were randomized to either a single IV infusion of 1,500 mg MEDI3902 (n = 85) or placebo (n = 83). Primary Efficacy endpoint was Endpoint Adjudication Committee-determined relative risk reduction (RRR) of PA pneumonia incidence in MEDI3902 vs. placebo recipients within 21 days post dose (2-sided α = 0.2). Serum MEDI3902 PK levels were measured through 49 days post dose. Treatment-emergent adverse events (TEAEs) and serious AEs (SAEs) were assessed through 49 days post dose. Results Baseline characteristics were similar between groups. MEDI3902 did not meet the primary endpoint of PA pneumonia vs. placebo (22.4% vs. 18.1%; RRR -23.7%, P = 0.491). Mean serum MEDI3902 level was 9.46 µg/mL (target 1.7µg/mL) at 21 days post dose, with a t½ 5.6 days. Proportion of subjects with TEAEs was similar between groups: ≥1 TEAE (98.8% MEDI3902; 97.6% placebo); ≥1 serious; and/or ≥grade 3 severity SAE (70.6% MEDI3902; 66.3% placebo). Deaths were numerically higher, although not statistically significant (24 (28.2%) MEDI3902 vs 19 (22.9%) Placebo; RRR -23.3%, P 0.429). Post-hoc analyses suggested RRR 47% among ~70% of the study population who had baseline Procalcitonin levels &lt; 0.55 µg/L (12.5% MEDI3902 vs 23.7% placebo; 80%CI 6.1%-69.9%; P 0.135). Similarly, RRR 83% was observed among 50% of study subjects with baseline absolute neutrophil count (ANC) of &lt; 8170 /µL (2.8% MEDI3902 vs 17.0% placebo; 80%CI 39.5%-95.5%; P 0.038). Subjects with Procalcitonin &lt; 0.55 µg/L and ANC &lt; 8170/ µL also had higher serum PK exposure. Conclusion A single IV dose of MEDI3902 provided PK exposure above the target level but did not achieve primary efficacy endpoint of reduction in PA pneumonia. Efficacy trends were observed in subjects with lower levels of baseline inflammatory biomarkers. MEDI3902 may have a path forward in certain patient populations such as ICU patients with lower baseline inflammation. Disclosures Jean Chastre, MD, AstraZeneca (Scientific Research Study Investigator) Marc Bourgeois, MD, AstraZeneca (Scientific Research Study Investigator) Apostolos Komnos, MD, PhD, AstraZeneca (Scientific Research Study Investigator) Ricard Ferrer, MD, PhD, Shionogi B.V. (Advisor or Review Panel member) Galia Rahav, MD, AstraZeneca (Scientific Research Study Investigator) Nicolas De Schryver, MD, AstraZeneca (Scientific Research Study Investigator) Alain Lepape, MD, AstraZeneca (Scientific Research Study Investigator) Miguel Sanchez Garcia, MD, PhD, AstraZeneca (Scientific Research Study Investigator) Antoni Torres, MD, PhD, AstraZeneca (Scientific Research Study Investigator) Omar Ali, PhD, AstraZeneca (Employee) Kathryn Shoemaker, MS, AstraZeneca (Employee) Alexey Ruzin, PhD, AstraZeneca (Employee, Shareholder) Yu Jiang, PhD, AstraZeneca (Employee) Susan Colbert, BSN, AstraZeneca (Employee) Drieke Vandamme, PhD, AstraZeneca (Scientific Research Study Investigator) Terramika Bellamy, n/a, AstraZeneca (Employee) Colin Reisner, MD, AstraZeneca (Employee) Filip Dubovsky, MD, MPH, AstraZeneca (Employee) Hasan S. Jafri, MD, FAAP, AstraZeneca (Employee)

Abstract Background: In metastatic Breast Cancer (mBC), Circulating Tumor Cells (CTCs) are clinical indicators of worse prognosis and indicate patients (pts) not responding to current therapy. However CTCs are rare, found in &lt; 20% of mBC pts, and many pts without CTCs may also progress. Recently an inflammatory pro-tumorigenic PD-L1 expressing macrophage (Cancer associated macrophage-like cell [CAML])was identified in the blood, which was found in &gt;90% of mBC pts and may indicate tumor response to new therapies (JCO 40[16_Suppl] 2022). SV-BR-1-GM is a mBC cell line derived with antigen presenting characteristics was developed for treatment of mBC as a monotherapy (monoTx), or in combination with checkpoint inhibitors (comboTx). We report preliminary post-hoc results of a pooled analysis of n=18 monoTx mBCs pts and interim results of n=15 comboTx to analyze the predictive value of CTCs & CAMLs, as well as CAML PD-L1 expression, isolated from pt peripheral blood pre & post treatment to predict drug response, with end point outcomes of Progression Free Survival (PFS) and Overall Survival (OS) at 24 months. Methods: The SV-BR-1-GM regimen includes low pre-dose cyclophosphamide, intradermal inoculation of ~20 million irradiated SV-BR-1-GM cells and post-dose local interferon-α with cycles every 2 weeks x 3, then monthly. ComboTx adds an anti-PD-1 antibody with cycles every 3 weeks. Blinded blood samples were taken at baseline (BL), prior to starting SV-BR-1-GM therapy (n=33), and a 2nd sample (T1) taken after therapy initiation (~52 days) obtained as part of the exploratory portion of 2 prospective phase I clinical drug studies, NCT03066947 & NCT03328026, to evaluate the predictive value of CTCs/CAMLs and CAML PD-L1 measured by LifeTracDx liquid biopsy. The quantities of CTCs & CAMLs were analyzed based on PFS using RECIST v1.1 and OS hazard ratios (HRs) by censored univariate analysis at 24 months. Results: A total of 33 mBC pts were pooled from monoTx (n=18), or comboTx (n =15), all with available blood samples at BL. CTCs were found in 30% (n=10/33) of pts at BL, and CAMLs were found in 94% (n=31/33) at BL. Presence of CTCs at BL did not correlate with worse PFS (HR=1.0, p=0.8550), but did trend for pts with worse survival (HR=5.1, p=0.0641). T1 samples were available from 61% (n=20/33) pts. A drop in CAMLs or CTCs after treatment at T1 was observed in 50% of pts, which correlated with a significantly improved PFS HR=11.8, p=0.0019 and OS HR=226.3, p=0.0397. Overall, pts with a decrease in CTCs/CAMLs after induction of SV-BR-1-GM therapy had a ~350% improvement in median PFS (1.9 mo. vs 6.6 mo.) and a ~200% improvement in median OS (6.3 mo. vs 12.4 mo). When stratified between monoTx and comboTx, pts with a decrease in CTCs/CAMLs had an improved PFS (HR 11.9, p=0.0136) in the monoTx group and an improved PFS (HR 17.5, p=0.0017) in the comboTx group. Further, while expression of CAML PDL1 at BL was not correlated with improved PFS (HR=1.0, p=0.9078), CAML PD-L1 expression at BL was correlated with significantly better OS HR=9.5, p=0.0116, consistent with long term benefit of SV-BR-1-GM therapy in this group of pts. Conclusions: We observed that treatment with the SV-BR-1-GM regimen was associated with decreases in the presence of CTCs and CAMLs in 50% of patients, which also significantly correlated with ~350% better median PFS and ~200% better median OS within 2 years. SV-BR-1-GM therapy alone, or as a combination treatment with anti-PD-1, appears to have improved long term clinical outcomes in a large portion of heavily pre-treated mBC patients compared to other typical standard of care published results. Citation Format: Daniel Adams, Mingjin Chang, Miguel Lopez-Lago, Cha-Mei Tang, William Williams, Giuseppe Del Priore. Decreases in Circulating Tumor Associated Cells Predicts PFS and OS In A Pooled Analysis Of Phase I Clinical Trials Using SV-BR-1-GM Therapy With Or Without Immune Check-Point Inhibitors In Metastatic Breast Cancer Patients [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P1-05-28.

Abstract Background: Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) is the most prevalent breast cancer (BC) subtype(≈60% of all BC in Spain), 95% of which are diagnosed in early stage. Despite several treatment options, approximately 20%-25% of them will experience metastatic relapse. Early and accurate identification of patients at high risk of recurrence is critical to improve patient outcomes. It would be relevant to know how high risk patients are identified and managed in Spain. The primary objective was to describe the current approaches to patient management and standards of care for patients with early stage (I-IIIc) HR+/HER2- BC in a real world setting in Spain.Methods: Real-world data were drawn from the Adelphi Early BC I Disease Specific Program. Data included physicians´ (medical oncologists) subjective perceptions such as factors used to determine patient´s risks of recurrence, and objective variables relating to the next 8 consecutive patients with HR+ HER2- BC they consulted and completed patient record forms for, such as demographic, clinical and gene expression profiles. Data were collected between June and October 2019. The sample was analyzed to identify patients similar to those meeting the high risk of recurrence criteria used in the monarchE (mE) trial: ≥4 positive nodes, OR 1-3 positive nodes AND [grade 3 or tumor ≥5 cm or Ki-67 ≥20%]. Those not meeting the criteria were categorised as Low/moderate (L/M) risk. Results: 50 oncologists provided data on 400 consecutive patients, of which 81 (20%) were categorized as high risk. Patients´ mean age was 58 years old at diagnosis and initiated first adjuvant treatment (AT) within four months of diagnosis. 19% had family history of BC, their disease stage was predominantly II (50%), 57% had grade 2 tumors and 74% had a tumor size of 1-3cm. 50 patients (13%) met high risk clinical pathologic criteria (≥4 positive nodes, OR 1-3 positive nodes AND [grade 3 or tumor ≥5 cm]) and an additional 31 patients (8%) met high risk mE criteria based on having a Ki-67 expression of ≥20%.At diagnosis, high risk patients compared to L/M tended to be younger (mean 54,3 vs 58,5 years), with higher likelihood of BC family history (32% vs 16%), more advanced disease at diagnosis (99% vs 59% stage II or III), more likely to have grade 3 tumors (41% vs 14%) and tumors &gt;3cm (32% vs 14%). The most common biomarker/genetic tests at diagnosis were ER, PgR and Ki67, used in over 95% of patients.Genomic assays of the tumors were performed in 35% of patients, of which the most common were Oncotype Dx (58%) and MammaPrint (22%). High risk patients were less likely to have genomic assays (15% vs 40% received any). Genomic assays were more often conducted prior to starting AT therapy (66%) than at initial diagnosis (38%).Neoadjuvant and first adjuvant treatments are described in table 1. Factors frequently considered by oncologists (&gt;45% of respondents) to evaluate risk of recurrence were tumor stage, size and grade, nodal, HER2 and HR status, genomic assays and Ki-67 expression level. Conclusion: One in five patients were classified as high risk according to mE criteria, although oncologists considered additional factors to categorize patients as high risk level in their daily practice. Consequently, many patients of L/M risk according to mE criteria could still be considered as high risk by their physicians, as suggested by nearly half of patients receiving ChT treatment as adjuvant therapy. Proportion of patients that were prescribed each class in each setting (not mutually exclusive)ChemotherapyAnthracyclineTaxaneEndocrine therapyAromatase inhibitorTamoxifenTargeted therapyTotal sampleNeoadjuvant therapy n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)Overall (n=400)75 (19)69 (92)60 (80)64 (85)28 (37)22 (29)6 (8)-High risk (n=81)17 (21)16 (94)15 (88)16 (94)8 (47)7 (41)1 (6)-L/M risk (n=319)58 (18)53 (91)45 (78)48 (83)20 (34)15 (26)5 (9)-Total sampleFirst adjuvant n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)Overall (n=400)400 (100)217 (54)129 (32)132 (33)256 (64)177 (44)79 (20)1 (0)High risk (n=81)81 (100)66 (81)56 (69)50 (62)27 (33)18 (22)9 (11)1 (1)L/M risk (n=319)319 (100)151 (47)73 (23)82 (26)229 (72)159 (50)70 (22)- Citation Format: Miguel Martín, Jose Ángel García Sáenz, Isabel Blancas, Alberto Molero, Manuel Atienza, Jose Manuel Cervera, Jacqueline Brown, Alex Rider, Rhys Williams, Emilio Alba. Patient profiles, management and treatment patterns in HR+, HER2- early breast cancer in a real-world setting in Spain [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-07-10.

En estas líneas presentamos el Nº 26 de la REJIE Nueva época que dedicamos a la memoria del profesor José Calvo González quien fuera Catedrático de Filosofía del Derecho de la Facultad de Derecho de la Universidad de Málaga. El profesor Calvo González desde el principio de la existencia de esta revista se mostró ilusionado y ofreció su incondicional apoyo como miembro de su Consejo de Redacción, como miembro de su Comité Científico Nacional, como evaluador y también autor de artículos. Es por ello que en este número queremos rendirle nuestro sentido y particular homenaje. Los profesores Felipe Navarro Martínez, Cristina Monereo Atienza y María Pina Fersini, colegas de Departamento del profesor Calvo, nos hacen una emotiva semblanza del mismo que han titulado “La vocación pedagógica e innovadora de José Calvo González”. Este homenaje se completa con la reedición del último artículo que el profesor Calvo publicó en el número 17 de nuestra Revista y que lleva por título “Imago iuris en la allegorie van justitia met doodzonden cultura visual del Derecho: la pictura del sistema inquisitivo europeo durante el S. XVI”. En este artículo, nos presentaba diversos problemas jurídicos a través de obras pictográficas. El profesor Calvo nos mostraba una novedosa técnica para la enseñanza y el aprendizaje de instituciones jurídicas, como el sistema inquisitivo en el Siglo XVI, mediante su plasmación en pinturas. El texto reflejaba cómo el Derecho se puede aprender a través de la tradicional obra escrita de una específica disciplina, pero también, a través de otras expresiones más sugerentes como la pintura, la literatura o el cine. Además de lo presentado, en este número se han publicado un total de cuatro artículos y tres recensiones. En el bloque sobre innovación docente, el primer artículo se titula “Estrategias docentes para la adaptación de la docencia en ciencias jurídicas al entorno on line y semipresencial”. Ha sido elaborado por una pluralidad de autores de la Universidad de Alicante y la Universidad Miguel Hernández: Raúl Ruiz Rodríguez, Carolina Soler García, Carmen María García Mirete, José Miguel Beltrán Castellanos, Francisco José Abellán Contreras, Lerdys Heredia Sánchez, Alfonso Ortega Giménez, Alicia Fernández-Peinado Martínez, Aitana Ramón Martín y Tamara Funes Beltrán. En este artículo, los autores presentan la planificación ordenada y estructurada que en el curso 2020-2021, como consecuencia de la pandemia, diseñaron para las asignaturas de Derecho Administrativo, Derecho Internacional Público, Cooperación Jurídica Internacional, Nacionalidad y extranjería, Derecho Penal Especial, Historia del Derecho y de las Instituciones, Derecho Procesal, Derecho Internacional Privado y Derecho del Trabajo. El objetivo de la planificación consistió en hacer uso de nuevas metodologías y/o herramientas virtuales adecuadas al nuevo contexto de enseñanza-aprendizaje, tratando de adaptar los contenidos y metodologías a este nuevo escenario e-learning, compartiendo sus diferentes estrategias docentes, para así tratar de alcanzar conclusiones y resultados en común. Los resultados del estudio son presentados de manera rigurosa y atractiva. El segundo artículo titulado “Experimentos intelectuales con máquinas: a propósito del utilitarismo y la teoría deontológica en el análisis de las teorías de la justicia” ha sido escrito por Fernando Centenera Sánchez-Seco, Profesor Contratado Doctor de Filosofía del Derecho en la Universidad de Alcalá. El autor expone un novedoso experimento pedagógico que, si bien puede asemejarse al método del caso o al método de resolución de problemas, va más allá, pues traslada al ámbito docente una metodología propia del ámbito investigador como es la réplica de estudios. El autor lleva a cabo dos prácticas en las que, teniendo como herramientas películas (Matrix, Imitatión Game y Código fuente) y textos (La máquina de experiencias de Robert Nozick), se presentan la teoría del utilitarismo y la teoría deontológica como teorías de la justicia con una proyección práctica, alejada de la concepción en lo abstracto en la que se ha venido anclando a la iusfilosofía. El autor presentadas las acciones prácticas, nos ofrece la evaluación y los resultados obtenidos a partir de la encuesta realizada por el alumnado participante en la experiencia docente. El trabajo termina con unas conclusiones finales y varias propuestas de carácter prospectivo, con las que el autor considera que puede mejorarse la implementación para próximas ediciones. El tercer y último artículo de este bloque lleva por título “Universidad para mayores: reinventarse e innovar en tiempos pandémicos” y ha sido realizado por Maribel Torres Cazorla, Profesora Titular de Derecho Internacional Público de la Universidad de Málaga. Este trabajo analiza la experiencia vivida por la autora en el Aula de Mayores+55 de la Universidad de Málaga durante el curso académico 2020/21. Partiendo de considerar esta actividad como una manifestación del ejercicio y disfrute del Derecho a la Educación a lo largo de toda la vida, la autora ofrece algunos datos de otros entornos universitarios de nuestro país, y de las alternativas que se han planteado para no interrumpir esta actividad, enmarcándolo en el cumplimiento del Objetivo de Desarrollo Sostenible 4 de la UNESCO consistente en garantizar una educación inclusiva, equitativa y de calidad y promover oportunidades de aprendizaje durante toda la vida para todos. El bloque dedicado a la investigación sustantiva contiene un solo artículo titulado: “La Discriminación múltiple en el derecho al acceso al empleo de la mujer: un análisis desde el enfoque de la justicia relacional y el feminismo”, escrito por Alejandra Ríos Pérez. Este artículo es el resultado de un TFM, del Máster en Abogacía dirigido por el Profesor José Luis Ruiz Santamaría, Profesor Ayudante Doctor de Derecho del Trabajo y la Seguridad Social de la UMA. El TFM fue calificado por el Tribunal con Matrícula de Honor y en él la autora se marcó como objetivo desarrollar el concepto de la discriminación múltiple desde el enfoque de género, para poder observar los instrumentos existentes en el ordenamiento jurídico español para hacer frente a las situaciones de discriminación en el acceso al empleo y estudiar su cabida en los mecanismos de protección existentes. La autora parte de un enfoque de género que permite poner el énfasis en las desigualdades por razón de sexo, y se recurre a una concepción feminista de la justicia, para poner en valor los trabajos feminizados y señalar los riesgos de no tener en cuenta a los distintos grupos de mujeres, pudiendo ocasionar que en la búsqueda de la igualdad de la mujer acaben generándose dinámicas opresoras hacia las mujeres en situación de mayor vulnerabilidad. Pero a su vez, este punto de vista es combinado con la metodología propuesta por el enfoque de la justicia relacional que permite detectar los vacíos de justicia de la relación jurídica observando: cómo es la interacción de las normas, cómo se articulan las relaciones sociales en base a estas y qué resultados arroja en términos de justicia. El número se cierra con tres reseñas. La primera, de Pilar Castro López sobre la monografía “Los Entes Locales ante la transición y sostenibilidad energética” de la profesora de la Universidad de Málaga, Isabel González Ríos, publicado en 2021 por la editorial Thomson Reuters Aranzadi, Cizur Menor. La segunda, de José Alberto España Pérez sobre la monografía “Las sanciones disciplinarias a los alumnos universitarios y no universitarios, en centros públicos y privados” del profesor de la Universidad Miguel Hernández, José Antonio Tardío Pato publicada en 2020 por el Ministerio de Educación y Formación Profesional. La tercera, de Alicia María Pastor García sobre la monografía “Derecho Internacional Público y catástrofes” del profesor de la Universidad de Málaga, Andrés Bautista-Hernáez publicada en 2021 por la editorial Tirant lo Blanch. Carmen María Ávila Rodríguez Subdirectora académica de la REJIE, Nueva época.

“Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 212 NOTICIAS / NEWS (“transfer”, 2017) 1) CONGRESOS / CONFERENCES: 1. 8th Asian Translation Traditions Conference: Conflicting Ideologies and Cultural Mediation – Hearing, Interpreting, Translating Global Voices SOAS, University of London, UK (5-7 July 2017) www.translationstudies.net/joomla3/index.php 2. 8th International Conference of the Iberian Association of Translation and Interpreting (AIETI8), Universidad de Alcalá, Madrid, Spain (8-10 March 2017) www.aieti8.com/es/presentation 3. MultiMeDialecTranslation 7 – Dialect translation in multimedia University of Southern Denmark, Odense, Denmark (17-20 May 2017) https://mmdtgroup.org 4. Texts and Contexts: The Phenomenon of Boundaries Vilnius University, Lithuania (27-28 April 2017) www.khf.vu.lt/aktualijos/skelbimai/220-renginiai/1853-texts-andcontexts- the-phenomenon-of-boundaries 5. 21st FIT World Congress: Disruption and Diversification Australian Institute of Interpreters and Translators (AUSIT), Brisbane, Australia (3-5 August 2017) www.fit2017.org/call-for-papers 6. 6th International Conference on PSIT (PSIT6) - Beyond Limits in Public Service Interpreting and Translating: Community Interpreting & Translation University of Alcalá, Spain (6-8 March 2017) www.tisp2017.com “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 213 7. International Conference: What Grammar Should Be Taught to Translators-to-be? University of Mons, Belgium (9-10 March 2017) Contact: gudrun.vanderbauwhede@umons.ac.be; indra.noel@umons.ac.be; adrien.kefer@umons.ac.be 8. The Australia Institute of Interpreters and Translators (AUSIT) 2016 National Conference Monash University, Melbourne, Australia (18-19 November 2017) www.ausit.org/AUSIT/Events/National_Miniconference_2016_Call_ for_Papers.aspx 9. 1st Congrès Mondial de la Traductologie – La traductologie : une discipline autonome Société Française de Traductologie, Université de Paris Ouest- Nanterre-La Défense, France (10-14 April 2017) www.societe-francaise-traductologie.com/congr-s-mondial 10. Working Our Core: for a Strong(er) Translation and Interpreting Profession Institute of Translation & Interpreting, Mercure Holland House Hotel, Cardiff (19-20 May 2017) www.iti-conference.org.uk 11. International conference T&R5 – Écrire, traduire le voyage / Writing, translating travel Antwerp , Belgium (31 May - 1 June 2018) winibert.segers@kuleuven.be 12. Retranslation in Context III - An international conference on retranslation Ghent University, Belgium (7-8 February 2017) www.cliv.be/en/retranslationincontext3 “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 214 13. 11th International Conference on Translation and Interpreting: Justice and Minorized Languages under a Postmonolingual Order Universitat Jaume I, Castelló de la Plana, Spain (10-12 May 2017) http://blogs.uji.es/itic11 14. 31è Congrès international d’études francophones (CIÉF) : Session de Traductologie – La francophonie à l’épreuve de l’étranger du dedans Martinique, France (26 June – 2 July 2017) https://secure.cief.org/wp/?page_id=913 15. Complexity Thinking in Translation Studies: In Search of Methodologies KU Leuven, Belgium (1-2 June 2017) www.ufs.ac.za/humanities/unlistedpages/ complexity/complexity/home-page 16. 1st International Conference on Dis/Ability Communication (ICDC): Perspectives & Challenges in 21st Century Mumbai University, India (9-11 January 2017) www.icdc2016-universityofmumbai.org 17. Lost and Found in Transcultural and Interlinguistic Translation Université de Moncton, Canada (2-4 November 2017) gillian lane-mercier@mcgill.ca; michel.mallet@umoncton.ca; denise.merkle@umoncton.ca 18. Translation and Cultural Memory (Conference Panel) American Comparative Literature Association's 2017 Annual Meeting University of Utrecht, The Netherlands (6-9 July 2017) www.acla.org/translation-and-cultural-memory 19. Media for All 7 – A Place in Between Hamad bin Khalifa University, Doha, Qatar (23-25 October 2017) http://tii.qa/en/7th-media-all-international-conference “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 215 20. Justice and Minorized Languages in a Postmonolingual Order. XI International Conference on Translation and Interpreting Universitat Jaume I, Castellón, Spain (10-12 May 2017) monzo@uji.es http://blogs.uji.es/itic11/ 21. On the Unit(y) of Translation/Des unités de traduction à l'unité de la traduction Paris Diderot University, Université libre de Bruxelles and University of Geneva (7 July 2017 (Paris) / 21 October 2017 (Brussels) / 9 December 2017 (Geneva) www.eila.univ-paris-diderot.fr/recherche/conf/ciel/traductologieplein- champ/index?s[]=traductologie&s[]=plein&s[]=champ 22. The Translator Made Corporeal: Translation History and the Archive British Library Conference Centre, London, UK (8 May 2017) deborah.dawkin@bl.uk 23. V International Conference Translating Voices Translating Regions - Minority Languages, Risks, Disasters and Regional Crises Europe House and University College London, UK (13-15 December 2017) www.ucl.ac.uk/centras/translation-news-and-events/vtranslatingvoices 24. 8th Annual International Translation Conference - 21st Century Demands: Translators and Interpreters towards Human and Social Responsibilities Qatar National Convention Centre, Doha, Qatar (27-28 March 2017) http://tii.qa/en/8th-annual-international-translation-conference 25. Complexity Thinking in Translation Studies: In Search of Methodologies KU Leuven, Belgium (1-2 June 2017) www.ufs.ac.za/humanities/unlistedpages/ complexity/complexity/home-page “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 216 26. 15th International Pragmatics Conference (IPrA 2017) – Films in Translation – All is Lost: Pragmatics and Audiovisual Translation as Cross-cultural Mediation (Guillot, Desilla, Pavesi). Conference Panel. Belfast, Northern Ireland, UK (16-21 July 2017) http://ipra.ua.ac.be/main.aspx?c=*CONFERENCE2006&n=1296 2) CURSOS, SEMINARIOS, POSGRADOS / COURSES, SEMINARS, MA PROGRAMMES: 1. MA in Intercultural Communication in the Creative Industries University of Roehampton, London, UK www.roehampton.ac.uk/postgraduate-courses/Intercultural- Communication-in-the-Creative-Industries 2. Máster Universitario en Comunicación Intercultural, Interpretación y Traducción en los Servicios Públicos Universidad de Alcalá, Spain www3.uah.es/master-tisp-uah 3. Máster Universitario de Traducción Profesional Universidad de Granada, Spain http://masteres.ugr.es/traduccionprofesional/pages/master 4. Workshop: History of the Reception of Scientific Texts in Translation – Congrès mondial de traductologie Paris West University Nanterre-La Défense, France (10-14 April 2017) https://cmt.u-paris10.fr/submissions 5. MA programme: Traduzione audiovisiva, 2016-2017 University of Parma, Italy www.unipr.it/node/13980 “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 217 6. MA in the Politics of Translation Cairo University, Egypt http://edcu.edu.eg 7. Research Methods in Translation and Interpreting Studies University of Geneva, Switzerland (Online course) www.unige.ch/formcont/researchmethods-distance1 www.unige.ch/formcont/researchmethods-distance2 8. MA programme: Investigación en Traducción e Interpretation, 2016-2017 Universitat Jaume I, Castellón, Spain monzo@uji.es www.mastertraduccion.uji.es 9. MA programme: Traduzione Giuridica - Master di Secondo Livello University of Trieste, Italy Italy http://apps.units.it/Sitedirectory/InformazioniSpecificheCdS /Default.aspx?cdsid=10374&ordinamento=2012&sede=1&int=web &lingua=15 10. Process-oriented Methods in Translation Studies and L2 Writing Research University of Giessen, Germany (3-4 April 2017) www.uni-giessen.de/gal-research-school-2017 11. Research Methods in Translation and Interpreting Studies (I): Foundations and Data Analysis (Distance Learning) www.unige.ch/formcont/researchmethods-distance1 Research Methods in Translation and Interpreting Studies (II): Specific Research and Scientific Communication Skills (Distance Learning) www.unige.ch/formcont/researchmethods-distance2 University of Geneva, Switzerland “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 218 3) LIBROS / BOOKS: 1. Carl, Michael, Srinivas Bangalore and Moritz Schaeffer (eds) 2016. New Directions in Empirical Translation Process Research: Exploring the CRITT TPR-DB. Cham: Springer. http://link.springer.com/book/10.1007/978-3-319-20358-4 2. Antoni Oliver. 2016. Herramientas tecnológicas para traductores. Barcelona: UOC. www.editorialuoc.com/herramientas-tecnologicas-para-traductores 3. Rica Peromingo, Juan Pedro. 2016. Aspectos lingüísticos y técnicos de la traducción audiovisual (TAV). Frakfurt am Main: Peter Lang. www.peterlang.com?432055 4.Takeda, Kayoko and Jesús Baigorri-Jalón (eds). 2016. New Insights in the History of Interpreting. Amsterdam: John Benjamins. https://benjamins.com/#catalog/books/btl.122/main 5. Esser, Andrea, Iain Robert Smith & Miguel Á. Bernal-Merino (eds). 2016. Media across Borders: Localising TV, Film and Video Games. London: Routledge. www.routledge.com/products/9781138809451 6. Del Pozo Triviño, M., C. Toledano Buendía, D. Casado-Neira and D. Fernandes del Pozo (eds) 2015. Construir puentes de comunicación en el ámbito de la violencia de género/ Building Communication Bridges in Gender Violence. Granada: Comares. http://cuautla.uvigo.es/sos-vics/entradas/veruno.php?id=216 7. Ramos Caro, Marina. 2016. La traducción de los sentidos: audiodescripción y emociones. Munich: Lincom Academic Publishers. http://lincom-shop.eu/epages/57709feb-b889-4707-b2cec666fc88085d. sf/de_DE/?ObjectPath=%2FShops%2F57709feb“ Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 219 b889-4707-b2cec666fc88085d% 2FProducts%2F%22ISBN+9783862886616%22 8. Horváth , Ildikó (ed.) 216. The Modern Translator and Interpreter. Budapest: Eötvös University Press. www.eltereader.hu/media/2016/04/HorvathTheModernTranslator. pdf 9. Ye, Xin. 2016. Educated Youth. Translated by Jing Han. Artarmon: Giramondo. www.giramondopublishing.com/forthcoming/educated-youth 10. Martín de León, Celia and Víctor González-Ruiz (eds). 2016. From the Lab to the Classroom and Back Again: Perspectives on Translation and Interpreting Training. Oxford: Peter Lang. www.peterlang.com?431985 11. FITISPos International Journal, 2016 vol.3: A Retrospective View on Public Service Translation and Interpreting over the Last Decade as well as the Progress and Challenges that Lie Ahead www3.uah.es/fitispos_ij 12. Dore, Margherita (ed.) 2016. Achieving Consilience. Translation Theories and Practice. Newcastle: Cambridge Scholars Publishing. www.cambridgescholars.com/achieving-consilience 13. Antonini, Rachele & Chiara Bucaria (eds). 2016. Nonprofessional Interpreting and Translation in the Media. Frankfurt am Main: Peter Lang. www.peterlang.com/index.cfm?event=cmp.ccc.seitenstruktur.detai lseiten&seitentyp=produkt&pk=82359&cid=5&concordeid=265483 14. Álvarez de Morales, Cristina & Catalina Jiménez (eds). 2016. Patrimonio cultural para todos. Investigación aplicada en traducción accesible. Granada: Tragacanto. www.tragacanto.es/?stropcion=catalogo&CATALOGO_ID=22 “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 220 15. Poznan Studies in Contemporary Linguistics, special issue on Language Processing in Translation, Volume 52, Issue 2, Jun 2016. www.degruyter.com/view/j/psicl.2016.52.issue-2/issuefiles/ psicl.2016.52.issue-2.xml?rskey=z4L1sf&result=6 16. Translation and Conflict: Narratives of the Spanish Civil War and the Dictatorship Contact: alicia.castillovillanueva@dcu.ie; lucia.pintado@dcu.ie 17. Cerezo Merchán, Beatriz, Frederic Chaume, Ximo Granell, José Luis Martí Ferriol, Juan José Martínez Sierra, Anna Marzà y Gloria Torralba Miralles. 2016. La traducción para el doblaje. Mapa de convenciones. Castelló de la Plana: Publicacions de la Universitat Jaume I. www.tenda.uji.es/pls/www/!GCPPA00.GCPPR0002?lg=CA&isbn=97 8-84-16356-00-3 18. Martínez Tejerina, Anjana. 2016. El doblaje de los juegos de palabras. Barcelona: Editorial UOC. www.editorialuoc.com/el-doblaje-de-los-juegos-de-palabras 19. Chica Núñez, Antonio Javier. 2016. La traducción de la imagen dinámica en contextos multimodales. Granada: Ediciones Tragacanto. www.tragacanto.es 20. Valero Garcés, Carmen (ed.) 2016. Public Service Interpreting and Translation (PSIT): Training, Testing and Accreditation. Alcalá: Universidad de Alcalá. www1.uah.es/publicaciones/novedades.asp 21. Rodríguez Muñoz, María Luisa and María Azahara Veroz González (Eds) 2016. Languages and Texts Translation and Interpreting in Cross Cultural Environments. Córdoba: Universidad de Córdoba. www.uco.es/ucopress/index.php/es/catalogo/materias- 3/product/548-languages-and-texts-translation-and-interpreting“ Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 221 in-cross-cultural-environments 22. Mereu, Carla. 2016. The Politics of Dubbing. Film Censorship and State Intervention in the Translation of Foreign Cinema in Fascist Italy. Oxford: Peter Lang. www.peterlang.com/view/product/46916 23. Venuti, Lawrence (ed.) 2017. Teaching Translation: Programs, Courses, Pedagogies. New York: Routledge. www.routledge.com/Teaching-Translation-Programs-coursespedagogies/ VENUTI/p/book/9781138654617 24. Jankowska, Anna. 2015. Translating Audio Description Scripts. Translation as a New Strategy of Creating Audio Description. Frankfurt: Peter Lang. www.peterlang.com/view/product/21517 25. Cadwell, Patrick and Sharon O'Brien. 2016. Language, culture, and translation in disaster ICT: an ecosystemic model of understanding. Perspectives: Studies in Translatology. www.tandfonline.com/doi/full/10.1080/0907676X. 2016.1142588 26. Baumgarten, Stefan and Chantal Gagnon (eds). 2016. Translating the European House - Discourse, Ideology and Politics (Selected Papers by Christina Schäffner). Newcastle: Cambridge Scholars Publishing. www.cambridgescholars.com/translating-the-european-house 27. Gambier, Yves and Luc van Doorslaer (eds) 2016. Border Crossings – Translation Studies and other disciplines. Amsterdam: John Benjamins. www.benjamins.com/#catalog/books/btl.126/main 28. Setton, Robin and Andrew Dawrant. 2016. Conference Interpreting – A Complete Course. Amsterdam: John Benjamins. https://benjamins.com/#catalog/books/btl.120/main “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 222 29. Setton, Robin and Andrew Dawrant. 2016. Conference Interpreting – A Trainer’s Guide. Amsterdam: John Benjamins. https://benjamins.com/#catalog/books/btl.121/main 5) REVISTAS / JOURNALS: 1. Technology and Public Service Translation and Interpreting, Special Issue of Translation and Interpreting Studies 13(3) Contact: Nike Pokorn (nike.pokorn@ff.uni-lj.si) & Christopher Mellinger (cmellin2@kent.edu) www.atisa.org/tis-style-sheet 2. Translator Quality – Translation Quality: Empirical Approaches to Assessment and Evaluation, special issue of Linguistica Antverpiensia, New Series (16/2017) Contact: Geoffrey S. Koby (gkoby@kent.edu); Isabel Lacruz (ilacruz@kent.edu) https://lans-tts.uantwerpen.be/index.php/LANSTTS/ announcement 3. Special Issue of the Journal of Internationalization and Localization on Video Game Localisation: Ludic Landscapes in the Digital Age of Translation Studies Contacts: Xiaochun Zhang (xiaochun.zhang@univie.ac.at) and Samuel Strong (samuel.strong.13@ucl.ac.uk) 4. mTm Translation Journal: Non-thematic issue, Vol. 8, 2017 www.mtmjournal.gr Contacts: Anastasia Parianou (parianou@gmail.com) and Panayotis Kelandrias (kelandrias@ionio.gr) “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 223 5. CLINA - An Interdisciplinary Journal of Translation, Interpreting and Intercultural Communication, Special Issue on Interpreting in International Organisations. Research, Training and Practice, 2017 (2) revistaclina@usal.es http://diarium.usal.es/revistaclina/home/call-for-papers 6. Technology and Public Service Translation and Interpreting, Special Issue of Translation and Interpreting Studies, 2018, 13(3) www.atisa.org/call-for-papers 7. Literatura: teoría, historia, crítica, special issue on Literature and Translation www.literaturathc.unal.edu.co 8. Tradumàtica: Journal of Translation Technologies Issue 14 (2016): Translation and mobile devices www.tradumatica.net/revista/cfp.pdf 9. Ticontre. Teoria Testo Traduzione. Special issue on Narrating the Self in Self-translation www.ticontre.org/files/selftranslation-it_en.pdf 10. Terminology, International Journal of Theoretical and Applied Issues in Specialized Communication Thematic issue on Food and Terminology, 23(1), 2017 www.benjamins.com/series/term/call_for_papers_special_issue_23 -1.pdf 11. Cultus: the Journal of Intercultural Communication and Mediation. Thematic issue on Multilinguilism, Translation, ELF or What?, Vol. 10, 2017 www.cultusjournal.com/index.php/call-for-papers 12. Translation Spaces Special issue on No Hard Feelings? Exploring Translation as an Emotional Phenomenon “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 224 Contact: severine.hubscher-davidson@open.ac.uk 13. Revista electrónica de didáctica de la traducción y la interpretación (redit), Vol. 10 www.redit.uma.es/Proximo.php 14. Social Translation: New Roles, New Actors Special issue of Translation Studies 12(2) http://explore.tandfonline.com/cfp/ah/rtrs-si-cfp 15. Translation in the Creative Industries, special issue of The Journal of Specialised Translation 29, 2018 www.jostrans.org/Translation_creative_industries_Jostrans29.pdf 16. Translation and the Production of Knowledge(s), special issue of Alif 38, 2018 Contact: mona@monabaker.com,alifecl@aucegypt.edu, www.auceg ypt.edu/huss/eclt/alif/Pages/default.aspx 17. Revista de Llengua i Dret http://revistes.eapc.gencat.cat/index.php/rld/index 18. Call for proposals for thematic issues, Linguistica Antverpiensia New Series https://lans-tts.uantwerpen.be/index.php/LANSTTS/ announcement/view/8 19. Journal On Corpus-based Dialogue Interpreting Studies, special issue of The Interpreters’ Newsletter 22, 2017 www.openstarts.units.it/dspace/handle/10077/2119 20. Díaz Cintas, Jorge, Ilaria Parini and Irene Ranzato (eds) 2016. Ideological Manipulation in Audiovisual Translation, special issue of “Altre Modernità”. http://riviste.unimi.it/index.php/AMonline/issue/view/888/show Toc “Transfer” XII: 1-2 (mayo 2017), pp. 212-225. ISSN: 1886-554 225 21. PUNCTUM- International Journal of Semiotics, special issue on Semiotics of Translation, Translation in Semiotics. Volume 1, Issue 2 (2015) http://punctum.gr 22. The Interpreters' Newsletter, Special Issue on Dialogue Interpreting, 2015, Vol. 20 www.openstarts.units.it/dspace/handle/10077/11848 23. Gallego-Hernández, Daniel & Patricia Rodríguez-Inés (eds.) 2016. Corpus Use and Learning to Translate, almost 20 Years on. Special Issue of Cadernos de Tradução 36(1). https://periodicos.ufsc.br/index.php/traducao/issue/view/2383/s howToc 24. 2015. Special Issue of IberoSlavica on Translation in Iberian- Slavonic Cultural Exchange and beyond. https://issuu.com/clepul/docs/iberoslavica_special_issue 26. The AALITRA Review: A Journal of Literary Translation, 2016 (11) www.lib.latrobe.edu.au/ojs/index.php/AALITRA/index 27. Transcultural: A Journal of Translation and Cultural Studies 8.1 (2016): "Translation and Memory" https://ejournals.library.ualberta.ca/index.php/TC/issue/view/18 77/showToc 28. JoSTrans, The Journal of Specialised Translation, issue 26 www.jostrans.org 29. L’Écran traduit, 5 http://ataa.fr/revue/archives/4518

This article addresses the theme of authoritarianism in Brazil, by reflecting on three fundamental concepts: anti-Semitism, Bolsonarism and education. For the development of the argumentation that supports the article thesis, three aspects will be highlighted: the first relates to the understanding of the historical-cultural configuration of Brazilian society, which amalgamates a kind of Brazilian-style authoritarianism; the second addresses the possible link between Bolsonarism and the elements of anti- Semitism, which were developed by Horkheimer and Adorno in 1947; and the third reinforces the need for critical self-reflection, as a practical manifestation of non-conformity and combating the diverse authoritarianisms in Brazil.Resumo Esse artigo aborda o tema do autoritarismo no Brasil, mediante a reflexão de três conceitos fundamentais: o antissemitismo, o bolsonarismo e a educação. Para o desenvolvimento da argumentação que sustenta a tese desse artigo, três aspectos serão destacados: o primeiro relaciona-se à compreensão da configuração histórico-cultural da sociedade brasileira, que amalgama o autoritarismo à brasileira; o segundo aborda a possível vinculação entre o bolsonarismo e os elementos do antissemismo, que foram desenvolvidos por Horkheimer e Adorno em 1947; e o terceiro insiste na necessidade da autorreflexão crítica, como manifestação prática de inconformismo e combate aos autoritarismos diversos no Brasil.ResumenEste artículo presenta el tema del autoritarismo en Brasil, a partir de la reflexión sobre tres conceptos fundamentales: antisemitismo, bolsonarismo y educación. Para el desarrollo de la argumentación que sostiene la tesis del artículo, se destacan tres aspectos: el primero se refiere a la comprensión de la configuración histórico-cultural de la sociedad brasileña, que concreta el autoritarismo al “estilo brasileño”; el segundo se refiere a un posible vínculo entre el bolsonarismo y los elementos del antisemitismo, que fueron desarrollado por Horkheimer y Adorno en 1947; y el tercero refuerza la necesidad de autorreflexión crítica, como una manifestación práctica de no conformidad y de lucha contra los diversos tipos de autoritarismo en Brasil.Palavras-chave: Autoritarismo, Antissemitismo, Bolsonarismo, Teoria Crítica e Educação. Keywords: Authoritarianism, Anti-Semitism, Bolsonarism, Critical Theory and Education.Palabras claves: Autoritarismo, Antisemitismo, Bolsonarism, Teoría Crítica y Educación.ReferencesADORNO, Theodor W. Educação após Auschwitz in ADORNO, Theodor W. Educação e Emancipação. Rio de Janeiro: Paz e Terra, 1995. (pp. 119-138).ADORNO, Theodor W. Educação Contra a Barbárie in ADORNO, Theodor W. Educação e Emancipação. Rio de Janeiro: Paz e Terra, 1995. (pp. 155-168).ADORNO, Theodor W. Teoria da Semiformação in PUCCI, Bruno; ZUIN, Antonio A. S; LASTÓRIA, Luiz A. C. Nabuco. Teoria Crítica e Inconformismo. Campinas: Autores Associados, 2010.ARENDT, Hannah. Origens do Totalitarismo: anti-semitismo, imperialismo, totalitarismo. São Paulo: Companhia da Letras, 1989.ARENDT, Hannah. A condição humana. Rio de Janeiro: Forense Universitária, 2017.BLANC, Aldir e BOSCO, João. Essa Mulher – Elis Regina, Rio de Janeiro: Warner, 1979. BRASIL, Constituição (1988). Constituição da República Federativa do Brasil. Brasília: Senado Federal, 2000.BRESCIANI, Maria Stella “A casa em Gilberto Freyre: síntese do ser brasileiro?” em CHIAPPINI, Ligia e BRESCIANI, Maria Stella (orgs.). Literatura e cultura no Brasil. São Paulo: Cortez, 2002.COHN, Gabriel Cohn. “Esclarecimento e Ofuscação: Adorno e Horkheimer hoje”. Revista Lua Nova: revista de cultura e política, no número 43, ano 1998.DARDOT, Pierre e LAVAL, Christian. A nova razão do mundo: Ensaio sobre a sociedade neoliberal. São Paulo: Boitempo, 2016.DARDOT, Pierre e LAVAL, Christian. Comum: Ensaio sobre a revolução no século XXI. São Paulo: Boitempo, 2017.DUNKER, Christian Ingo Lenz. Psicologia das massas digitais e análise do sujeito democrático in ABRANCHES, Sérgio et al. Democracia em Risco? São Paulo: Companhia das Letras, 2019.FAORO, Raymundo. Os Donos do Poder: Formação do patronato político brasileiro. São Paulo: Globo, 2001.FOLHA DE SÃO PAULO. Matéria de 17/01/2020 “Em vídeo, Alvim copia Goebbels e provoca onda de repúdio nas redes sociais” in: https://www1.folha.uol.com.br/ilustrada/2020/01/em-video-alvim-cita-goebbels-e-provoca-onda-de-repudio-nas-redes-sociais.shtml. Acesso em 23 de maio de 2020.FOLHA DE SÃO PAULO. Matéria de 26/01/2020 “Veja falas preconceituosas de Bolsonaro e o que diz a lei sobre injúria e racismo” in https://www1.folha.uol.com.br/poder/2020/01/veja-falas-preconceituosas-de-bolsonaro-e-o-que-diz-a-lei-sobre-injuria-e-racismo.shtml. Acesso em 23 de maio de 2020.FOLHA DE SÃO PAULO. Matéria de 27/05/2020 “Decisão do supremo cita ‘gabinete do ódio’ do Planalto e indica possível associação criminosa” in: https://www1.folha.uol.com.br/poder/2020/05/decisao-de-moraes-para-operacao-contra-fake-news-cita-gabinete-do-odio-e-assessores-de-bolsonaro.shtml. Acesso em 03 de junho de 2020.FREIRE, Paulo. Educação como Prática da Liberdade. Rio de Janeiro: Paz e Terra, 1974.FREIRE, Paulo. Pedagogia do Oprimido. Rio de Janeiro: Paz e Terra, 1982.FREYRE, Gilberto. Casa Grande e Senzala: formação da família brasileira sob o regime da economia patriarcal. São Paulo: Círculo do Livro, 1933. FREYRE, Gilberto. Sobrados e Mucambos. São Paulo: Global, 2006.FURTADO, Celso. Formação Econômica do Brasil. São Paulo: Companhia das Letras, 2007.GOMES, Luiz Roberto. Autoritarismo y educación en Brasil. In: Miguel Vedda; Renato Franco; Antônio Álvaro Soares Zuin. (Org.). Estado de excepción en Argentina y Brasil: una perspectiva a partir de la teoría crítica. 1ed. Buenos Aires: Ediciones Herramienta, 2020.HOLLANDA, Sérgio Buarque de. Raízes do Brasil. São Paulo: Companhia das Letras, 1995.HONNETH, Axel. Luta por Reconhecimento: a gramática moral dos conflitos sociais. São Paulo: Editora 34, 2009.HORKHEIMER, Max e ADORNO, Theodor W. Elementos do Anti-semitismo: limites do esclarecimento in HORKHEIMER, Max e ADORNO, Theodor W. Dialética do Esclarecimento. Rio de Janeiro: Zahar, 1985 (pp. 157-194).HORKHEIMER, Max e ADORNO, Theodor W. Dialética do Esclarecimento. Rio de Janeiro: Zahar, 1985.IANNI, Octavio. Estado e Planejamento Econômico no Brasil. Rio de Janeiro: Civilização Brasileira, 1991.KANT, Immanuel. Crítica da Razão Pura. Rio de Janeiro: Vozes, 2015.LASTÓRIA, A. C. Nabuco e GOMES, Luiz Roberto. Educação para a emancipação ou para a personalidade flexível: uma análise política das expectativas em relação ao sistema In: LASTÓRIA, L. A. C. N; ZUIN, A. S.; GOMES, L. R e GRUSCHKA, A. (orgs). Teoria Crítica - Escritos sobre Educação: Contribuições do Brasil e Alemanha. São Paulo: Nankin, 2015.LEAL, Victor Nunes. Coronelismo, Enxada e Voto: o município e o regime representativo no Brasil. Rio de Janeiro: Editora Nova Fronteira, 1997.NEGT, Oskar e KLUGE, Alexandre. O que há de político na política? São Paulo: UNESP, 1999.PRADO JÚNIOR. Caio. Formação do Brasil Contemporâneo: colônia. São Paulo: Brasiliense; Publifolha, 2000.RIBEIRO, Darcy. O povo brasileiro: a formação e o sentido do Brasil. São Paulo: Companhia das Letras, 1995.ROCHA, João Cesar de Castro. “As origens e os equívocos da cordialidade brasileira” em Nenhum Brasil Existe – pequena enciclopédia. Rio de Janeiro: UniverCidade Editora, 2003 (p. 205-219).SOUZA, Jessé. A radiografia do Golpe: entenda como e porque você foi enganado. Rio de Janeiro: Leya, 2016.SOUZA, Jessé. A Elite do Atraso: da escravidão a Bolsonaro. Rio de Janeiro: Estação Brasil, 2017.SOUZA, Jessé. A Classe Média no Espelho: sua história, seus sonhos e ilusões, sua realidade. Rio de Janeiro: Estação Brasil, 2018. WEINSTEIN, Marc. Pensar el Totalitarismo Neoliberal: seis teses sobre totalitarismo. Constelaciones: Revista de Teoria Crítica. Madrid. Número 10 (2018), pp. 74-115.e4532136

Mirjana POLIĆ BOBIĆ: Kalifornijski zapisi oca Ferdinanda Konšćaka iz Družbe Isusove, Hrvatska sveučilišna naklada, Zagreb, 2015.U ovoj knjizi autorica je iscrpno i kompetentno, kao ponajbolji prevodilac pisane ostavštine Ferdinanda Konšćaka, analitički i metodološki kvalitetno, uz podrobna objašnjenja i popratna razmišljanja, na tristo stranica predstavila bogatu i vrijednu pisanu ostavštinu kao i relevantne spise o njegovom radu i o njemu. To je do sada najsveobuhvatniji pristup obradi spisa ovoga pripadnika Družbe Isusove u nas, koji uvelike pridonosi spoznaji o veličini i značenju njegovih znanstvenih i istraživačkih dosega, ne samo za geografiju nego za pojedine druge znanosti. Opsežni uvod čine četiri poglavlja autoričine sveobuhvatne rasprave 1. o Konšćakovim zapisima i životu s popisom i opisom rukopisa i izdanja Konšćakovih tekstova o Novom svijetu i o njegovu životu, 2. o tome kako je Konšćak mogao dospjeti u Donju Kaliforniju, 3. o Kaliforniji od mita do utopijskog projekta te 4. o kraljevskim i misionarskim interesima, utopijskim obrascima i svakodnevnici sa zaključnim razmatranjima. Spisateljičina rasprava o navedenim aspektima, opservacije i razmatrani predlošci brojnih prethodnika, suvremenika i kasnijih istraživača i promicatelja Konšćakova rada i djela odaju vrsnu poznavateljicu brojnih predložaka i dokumentacije, neobjavljene i objavljene, dostupne i manje dostupne o našem isusovcu istraživaču. Drugi dio, može se slobodno istaknuti, krucijalni su prijevodi petnaestak autentičnih zapisa, dakle pisama, izvješća, dnevnika, opisa, Ferdinanda Konšćaka iz kojih se neposredno saznaje o njegovim putovanjima, otkrićima, spoznajama, poslanju, sukobljavanjima pa sve do intimnijih razmišljanja u prepisci ili izviješćima kroz koja izbija mnoštvo dokaza o njemu kao o izrazitom isusovačkom humanistu, entuzijastu, misionaru i istraživaču. To su pisma subraći, nadređenima, meksičkom provincijalu, superiorima, vizitatorima, prijateljima, dnevnici i dr., te također dva prijevoda drugih autora Miguela del Barca i oca Francisca Zevallosa koji se tiču Ferdinanda Konšćaka. Djelo prate i zahvala, popis izvora uz prevedene Konšćakove tekstove, literatura, sažetci na španjolskom i engleskom jeziku i kratki opis života i rada autorice. Otac Ferdinand Konšćak, poznat u svjetskoj literaturi i kao Ferdinando Consag (španj.) utemeljitelj Donje Kalifornije (Baja California), rođen je u Varaždinu 2. prosinca 1703., a umro je u misiji Santa Gertrudis u Donjoj Kaliforniji (Meksiko) 10. rujna 1759. Pristupio je isusovačkom redu 1719. u Trenčinu u Slovačkoj. Filozofiju je završio u Grazu, zatim radio na kolegijima u Zagrebu, pa Budimu. Prije završetka studija teologije u Grazu, odobren mu je odlazak u Novi svijet pa je 1729. otišao u Španjolsku, odakle je iz Cadiza 1731. krenuo u jednom od jedrenjaka flote za Indije. Preko Havane, stigao je u Veracruz te u Meksiko gdje je 1731. završio započeti studij teologije. Na poluotok Donje Kalifornije stigao je 1732. u redukciju Loreto gdje je najprije boravio, pa 1733. prešao u San Ignacio, zatim na sam jug poluotoka, pa ponovno u San Ignacio odakle je opsluživao velik dio izoliranih krajeva, dajući posebno velik doprinos osnivanju misija Santa Gertrudis i San Francisco de Borja. Kao isusovački misionar postao je jedan od najslavnijih istraživača meksičkoga poluotoka Kalifornije, koji je dokazao da je Kalifornija poluotok. Naime, poslije ranijih spoznaja (još od 30-ih godina 16. st.) da je Donja Kalifornija poluotok (v. Planciusov zemljovid svijeta 1592., i Meteliusov Kalifornije 1598.), u 17. i početkom 18. stoljeća počeli su se u Europi pojavljivati pogrješni, dosta tvrdokorni stavovi da je riječ o otoku kao i zemljovidi na kojima je tako i prikazivana. Stoga je trebalo ponovno, a iz sasvim pragmatičnih razloga, podastrijeti nove dokaze o poluotoku. Premda se već subrat Francisco E. Kino u četiri svoja putovanja 1697. – 1702. uvjerio da je Kalifornija poluotok, to otkriće nije bilo prihvaćeno pa su se tražili novi dokazi. Konšćakovo istraživanje dokazalo je drugi put poluotočnost Donje Kalifornije. Čak je i kasnije bilo dvojbi o poluotočnosti pa je 1766. tamo poslan otac Wenceslao Linck da provjeri Konšćakovu tvrdnju. Priznati su mu znanstveni doprinosi u matematici, astronomiji, prirodoslovlju, etnologiji, geografiji i geologiji. Bio je graditelj cesta, vodoopskrbnih objekata i obrambenih nasipa te nadzornik svih isusovačkih misija u Meksiku, a njegovo ime nosi otočić Roca Consag (Consag Rocks na sjeveru Kalifornijskog zaljeva 17 milja od grada San Felipe). Miguel del Barco, kojeg je kasnije iščitavao i Alexander von Humboldt, navodio je Konšćaka kao važnog izvora opisa ratničkih običaja, društvenog ustroja tamošnjih indijanskih zajednica, njihovih jezika, vjerovanja, načina odijevanja, prehrambenih navika, obreda uvođenja u zrelo doba života. Uz brojne pohode, poduzeo je i tri veće ekspedicije (1746., 1751. i 1753.) u kojima je sustavno istraživao neznana područja poluotoka. U prvoj do ušća Rio Colorada, razriješio je više od dva stoljeća podržavanu dvojbu o Donjoj Kaliforniji, dokazavši da nije otok nego poluotok. Oko 1748. izradio je precizan zemljovid Donje Kalifornije, a oko 1750. i zemljovid Kalifornijskog zaljeva, ucrtavši u njih brojna naselja, misije, imena zaljeva, rtova, otoka, pojave vode (na njegovu zemljovidu Aguage) itd. kao i imena plemena. Zanimljivi su prikazi reljefa, posebice vulkanskog područja Las Virgenes (en los quales sehàn de scubierto Volcanes d Fuego. Año 1746), zaljeva, rtova, otoka i otočića u Kalifornijskom zaljevu itd. U svim ekspedicijama bilježio je podatke o terenu, prirodnim bogatstvima i starosjediocima. Osnovao je nove misije, gradio akvadukte, nasipe, kanale za odvodnju, sudjelovao pri otvaranju prvih rudnika srebra na poluotoku. Još za života objavljeni su njegovi dnevnici ekspedicijâ, prevedeni na nekoliko jezika, u više izdanja, a njegovi zemljovidi poluotokâ i zaljevâ bili su poznati u to doba i nerijetko precrtavani. U prvom pohodu 1746. Konšćak je s posadama i pratnjom na četiri jedrenjaka, počevši od luke San Carlos (daje opširan opis luke, voda, rtova), najbliže misiji San Ignacio, uz istočnu obalu poluotoka istražio najprije širi prostor zaljeva Santisima Trinidad (lovište bisernica s hridinastim dnom, opasnim za ronioce, San Bernabé i otočić s tuljanima). Nastavili su do područja rta San Juan de Bauptista, niske obale s glinenim nanosima, pojavom vode i priobalnim hridima što opširnije opisuje, zatim do rta San Miguel, koji sa sljedećim rtom zatvara zaljev, s barom, vrelom vode, lovištem bisernica, gdje za nevremena more izbacuje mnoštvo školjaka tvoreći nasip koji već kršteni domoroci nazivaju Pepena. U mjestu San Miguel de la Peña održali su poduku domorocima poganima, od kojih su neke i krstili. Dalje opširno opisuje obalu, vrste dna, odvaljene litice, pojave ilovasta tla uz obalu s kaktusom cardón i čičkom, brojnim pticama, pojavama mramora. U blizini rta San Gabriel de las Almeja ili Salsipuedes (prema imenu susjednog otočja) spominje otočić Tortuguilla (tj. Kornjačica) koji Kalifornijci nazivaju Serro Blanco, obližnja naselja u kojima je bilo ponešto krštenika. Domoroci skupljaju vodu, pa makar i slankastu jer su izvori rijetkost. Dno je opasno, hridinasto, spominje neku žutu pećinu, s opisom obale. Skupine domorodaca dovodile su djecu na krštenje, ali bilo je i onih, na koje su bili upozoreni da spremaju napad na ekspediciju, pa su nastavili prema zaljevu San Rafael gdje su na ušću rijeke Kada Koaman u razgovorima s gostoljubivim domorocima, koji su ih vodili do brzaca vode i zdenca, saznali da njih i ronioce napadaju gorštaci. Posebno je važan opis toplih vrela koja su vidljiva za oseke, a za plime su poplavljena morem, priobalnih dijelova s konkavnim stijenama s izvorima vode, šljunčanim i pješčanim nanosima, drvećem mezquite. Pohod je nastavljen prema rtu San Antonio. Tamošnjem malom zaljevu dali su ime Purgatorio (Čistilište). Zatim su obišli stjenoviti i hridinasti rt Las Animas i stigli u duboku i pogodnu uvalu Los Angeles zaštićenu ulančenim otocima na ulazu s pojavom vode koja teče sa strmih padina. Ovdje su bili izloženi prijetnjama okupljenih domorodaca sa sjevera koji su brodove pratili nekoliko dana. Nastavili su do dijela Los Remedios s uvalom Nostra Señora de los Remedios, s nasuprotnim otokom Angel Santo de la Guarda. Za njega navodi da je dosta izdužen, širi na sjeverozapadu i da se od rta San Rafael proteže sve do otočića San Juan i San Pablo, a i dijelu obale su dali isto ime. Svugdje ima dosta bisernica. Kanal između otoka i obale poluotoka pun je kitova pa ga zovi Kitovim tjesnacem (Canal de Ballenas). Skromne, guste i bljutave vode našli su i na dijelu obale koji su nazvali po danu dolaska, San Pedro e Pablo. Nastavili su do zaljeva San Luis Gonzaga i njegova otoka okruženog rtovima, povoljnog za sidrenje, s više slanih lokava na kopnu i bogat ribom, a na zemljovidu je ovdje označeno ime na kopnu San Stanislao (sv. Stanislav; poljski isusovac iz 16. st.). Tu se nalazi i voda San Estanislao. Stalno su susretali negostoljubive, preplašene domoroce, a u moru posvuda sedefaste školjke. Sljedećem dijelu obale nadjenuli su ime San Sebastian, a zatim dio obale zvan Visitación završava na sjeveru istoimenim visokim rtom. Dalje je obala niska, ravna, blatna i kamenita, s dosta antilopa, divljih koza i ovnova, a naišli su i na ključalo sumporno vrelo s dimom (zacijelo solfatar). Sljedeća zona, nazvana Santa Ysabel, zadnje je nalazište školjaka bisernica, jer ih dalje nije bilo, a u blizini, na dijelu dosta teško pristupačne obale s pješčanim prudovima s dražicom San Fermin našli su pitku vodu. Nastavili su prema uvali San Felipe de Jesús, a prošavši San Buonaventuru, obala je postala niska, pješčana, močvarna (Marismas na zemljovidu) s planinama udaljenima tri do četiri lige, bez uvala i izvora, s plitkim morem (Pantanas), zamuljeno. Stigavši do ušća Crvene rijeke, vode su postale obojene, opore, nezdrave. Unatoč vrlo teškim uvjetima, naišli su na pitku vodu pri ušću, na kojem rukavci rijeke odvajaju tri niska močvarna otoka. Nanos rijeke prostire se miljama, a snaga plimnih valova, kao i same rijeke, dovodila je do havarija pa je jedan od brodova stradao. Istražili su područje oko ušća, ustanovivši da s kalifornijske strane rijeka vijuga i među planinama. Nakon dvadeset pet dana istraživačkog pohoda, Konšćak prvi put spominje zemljovid koji je izrađivao navodeći: „Petnaestorica naših kretala se jedno vrijeme kopnom, pa su nam donijeli vijesti o stanju u močvari koja se nalazi na samom rtu toga podvodnoga područja i mi to ucrtasmo u zemljovid“ na kojem je bila označena sjeverna širina. Ovaj Konšćakov dnevnik otac Miguel de la Barca kasnije je popratio podrobnim objašnjenjima i komentarima. U drugoj ekspediciji Konšćak je putovao kopnom poluotoka prema sjeveru i do Tihog oceana. Taj pohod o kojem piše u pismu prijatelju i posebno opširno u dnevniku, odvijao se 1751. iz misije San Ignacio, zapravo iz La Piedad (kasnije nazvana Santa Gertrudis) prema San Everardu kroz Sierra Madre na drugu stranu poluotoka do Oceana. Pohod se odvijao uz pomoć konja, najprije u bezvodnom kraju s bodljikavim stablima milapa, gdje su domoroci već bili pokršteni. Zatim su stigli do korita Kalmayia, koje je pripadalo oselju Nuestra Señora dela Visitación, zatim do Nuestra Señora dela Desponsación de Pui te potoka Kanjaikamána, Nakon nekoliko dana došli su do Ajavaiamina, tekućice s vodom, potom do Anguma, potoka Ziénage u Mezcalu, nešto sjevernije. U dnevniku spominje otoke u tjesnacu Santa Barbara i otok Cerros (Cedros) ili Santisima Trinidad, koji domoroci zovu Vamalgua ili (G)Uamalgua (tj. kuća magle) te rt Mendocino i otok Cenizas na Oceanu. Došavši do mjesta Kalvalaga pogled im se pružio na mali, ali visok otok „koji pomorci koji putuju za Filipine zovu Guadalupe“. Odatle su se vratili natrag do potoka Ziénage i potoka Kanjaikamána, te se zadržali kod vrela Medakal. Slijedi opis obale nasuprot otoku Cedros, gdje ima u moru mnoštvo kitova, gdje su pronašli ostatke brodoloma nekog broda, a spominje i Zaljev (očito Vizcaíno). Uskoro su stigli u indijanski Laboakal, odakle su se ponovno vratili u La Piedad i San Everardo, odakle su i krenuli. Svugdje opisuje život, vjerovanja, ponašanja i običaje domorodaca. Iz vremena između drugog i trećeg pohoda, posebno je važan opis otkrivenih dijelova Kalifornije i dijelova Meksika. Najprije za Donju Kaliforniju kaže da je siromašna, bezvodna, s nešto ruda i bisernicama, u nju misionari dolaze iz svojih misija u Sinaloi, na koju se kratko osvrće. Misije su geografski razmještene od najjužnije San Lucas do najsjevernije Santa Gertrudis. Plodnog zemljišta ima samo na jugu, i tamo žive u bolestima i međusobnim sukobima vrlo razrijeđeni Perikujci i Vajkurci te Guajkurci. Tri misije Perikujaca, Santa Rosa, Santiago i San José del Cabo, svedene su na Santiago i seoce San José, a vajkurske su misije Nuestra Señora de Pilar na jugu i Nuestra Señora de los Dolores i San Luis Gonzaga nešto sjevernije s oceanske strane. Ishodište misijskog rada i kraljevskih snaga je Loreto, nekad Concho, u području malobrojnog naroda Monkujaca, jezikom različitog od drugih, a okružuje ga prostorno istaknut narod Kočimaca ili Lajmona. Tamo je sedam misija (od juga prema sjeveru: San Javier, San José de Comondú, Purísima Concepción, Santa Rosalia, Nuestra Señora de Guadelupe, San Ignacio i Santa Gertrudis). Opisuje različitost narječja plemena, njihovih običaja te napose način jedenja (s uzicom uz dvostruko žvakanje). Poluotokom se pruža bezvodno sredogorje Sierra Madre, a priobalje je još bezvodnije pa su samo tri misije na obali. Otvoreni su i rudnici (Santa Anna i dr.). Ima nešto srebra, dosta naslaga soli i salitre. Uz poluotok su i otoci, s oceanske strane su važniji Santa Magdalena, La Navidad de Nuestra Señora i Cerros (Uamalgua). S ovoga posljednjeg domoroci su prešli na kopno i dio ih se naselio u San Estanislau. Bave se i lovom na morske dabrove (nutrije). S istočne strane poluotoka ima više pogodnih luka (Concepción, Los Angeles i dr.), zaljeva te otoka, od kojih su za pristajanje pogodna tri: Espíritu Santo (za plime dva otoka, vrelo vode), San José (domoroci tamo love divljač koja u želudcima ima bezoar, kamen koji stvaraju preživači i ima ljekovita svojstva) i onaj posvećen Gospi Karmelskoj na kojem je solana. Navodi da su svi otoci Kalifornijskog zaljeva nenaseljeni, premda je na nekima prije bilo stanovnika, ali su prešli na kopno u misije. Opisuje različitost školjki bisernica i samih bisera prema boji (na jugu su bijeli, sjevernije u raznim bojama) s kojima se trguje, purpurnu školjku, a ističe da su brojne i zmije te morske kornjače s obje strane poluotoka, ali onih s prozirnim oklopom koje daju skupu kornjačevinu ima samo na jugu. Bavi se i različitim biljkama (medesa, agave, tedá, gorka smokva, kaktusi, razni sukulenti, garambulla, pitahaye, cardón, portulak, šćir) od kojih su neke jestive, ljekovite, a za prehranu su važni i zečevi, kunići, šišmiši pa i štakori. Česti su leopardi, rjeđi jaguari, divlje mačke, vukovi, ima kojota, a lisice su brojne, i sve ih domoroci jedu. Otrovnice čegrtuše su posvuda kao i brojne druge, većinom neotrovne zmije. Spominje i guštere i crve koje domoroci sve jedu osim daždevnjaka i nekoga crvenog crva, te pojedine kukce (stjenice, skakavce, razne pauke pa i tarantule i dr.). Od ptica spominje brojne grabljivice, orlove, gavrane te golubove, neke vrste nalik na fazane i prepelice. Srebro se vadi u rudnicima na jugu, bakra ima po kamenju, željeza također u grumenima, sumpora u izobilju, galice, različitih mramora i prozirca nalik na dijamant. Daje opširne opise običaja i životnih navika domorodaca, muškaraca i žena, nošnje, ženidbe, vjerovanja, idola, vračeva, glazbe, plesova, mnogoženstva (naročito kod stasitih i svijetloputih Perikujaca), vještina lova, prehrane, pogrebnih običaja, inicijacije itd. Vrlo pojednostavnjeno daje opise pojedinih stijena, ruda, okamina, konglomerata i breča pokušavajući objasniti njihov postanak. Na kraju u bilješci navodi luke s oceanske strane kad se od otoka Cerros putuje na sjever: San Hipólito i San Damián prije otoka Cenizas, a zatim San Francisco (de Borja, op. p.), Las Vírgenes, San Simón i Judas te San Diego, koji je razmjerno blizu misije San Borja. Treći pohod 1753. godine, čiji izvorni opis (dnevnik) do sada nije poznat, ali se ponešto saznaje iz drugih napisa, ostvaren je kroz unutrašnjost poluotoka na sjever do 30. stupnja sjeverne širine. Ovaj je put prošao u puno gostoljubivijem okruženju domorodaca, kopnom od Santa Gertrudis preko naselja uz zaljev Los Angeles, do naselja u sredogorju nedaleko od zaljeva San Luis Gonzaga. Osim što je brojnim pothvatima osnivao sigurna naselja, vodoopskrbne sustave, smirivao sukobe među plemenima, onemogućavao pljačke s različitih strana, počeo opismenjavati i liječiti domoroce od zaraza i epidemija, otvarajući im tako put u civilizirani način života, za geografe su značajni i njegovi pisani doprinosi. Uz manje opservacije o Havani, Veracruzu, otocima Alacranes u Meksičkom zaljevu, otkrio je svjetskoj geografskoj spoznaji oblik i zemljopisna obilježja istočne obale Donje Kalifornije, duljinu otoka Angel de la Guarda, mjesto za misiju San Francisco de Borja, izvor rijeke Adac. Istražujući terene oko misija San Ignacio, koji je na granici prema sjeveru (frontera del Norte), Santa Gertrudis, te velik dio Kalifornijskog zaljeva (ili Crvenog mora), u njegovim se zapisima ističu misija Guadelupe, oblast Primeria (današnje Sonora i Sinaloa), ušće Crvene rijeke, temeljit opis zaljeva Los Angeles, vrlo pogodne prirodne luke s vrelima vode i više otočića u blizini (južno od Kanala kitova Canal de Ballenas na njegovoj karti) s pogodnim pristupom iz luka Caborce i Tepoce, koji, s obzirom na povoljne vjetrove, omogućuje prolaz kroz „zastrašujuće otoke Salsipuedes“, Laogiú, tj. planine San Rafael i mnoge druge u ovom tekstu navedene. Geografi, ali i svi drugi koje ova problematika zanima, u ovom će zanimljivom štivu zahvaljujući trudu autorice, pronaći poticaje za saznanja o Ferdinandu Konšćaku i njegovim otkrićima i zapisima, a možda i za daljnje pronalaženje drugih, do danas još nepoznatih rukopisa, bilo njegovih ili o njemu. Autorica Polić Bobić je za knjigu o ocu Ferdinandu Konšćaku dobila nagradu Hrvatske akademije znanosti i umjetnosti za najviša znanstvena i umjetnička dostignuća u Republici Hrvatskoj za 2015. godinu za područje društvenih znanosti Mirjana POLIĆ BOBIĆ, Mijo KORADE: Paragvajska pisma: Ivan Marchesetti i Nikola Plantić, isusovci u Paragvajskoj provinciji Družbe Isusove, Matica hrvatska, Zagreb, 2015. Iz pera vrsne hispanistice, urednice i književne prevoditeljice, redovite profesorice španjolske i hispanoameričke književnosti na Filozofskom fakultetu Sveučilišta u Zagrebu te koautora, crkvenog povjesničara i povjesničara kulture, suradnika Hrvatskog instituta za povijest u Zagrebu i nasl. redovitog profesora na Hrvatskim studijima Sveučilišta u Zagrebu, dostupno je široj javnosti kulturološko ostvarenje koje ima i brojne sastavnice povijesno-zemljopisne naravi, pa je stoga zanimljivo ne samo za povjesničare, hispaniste i druge, nego posebice i za geografe. Prof. Polić Bobić inače se bavi istraživanjem književnosti i kulturne povijesti kolonijalne Amerike te hrvatsko-hispanskim kulturnim vezama, a prof. Mijo Korade hrvatskom latinističkom historiografijom, historiografijom hrvatskoga redovništva, odnosima Crkve i države, poviješću školstva u Hrvata i hrvatskim putnicima i putopiscima. Knjiga se u prvom dijelu bavi Paragvajskom provincijom Družbe Isusove i njezinim misijama u kojima su srednjoeuropski isusovci, među kojima i hrvatski, u okviru opće i kulturne povijesti kolonijalne Amerike dali istaknut doprinos ne samo zemljopisnom širenju misijskih projekata, nego i sveukupnom udjelu Družbe Isusove u kulturi, povijesti, geografiji, književnosti itd. kolonijalnih posjeda. Razmatranim spisima te redovničke pokrajine, u kojoj su o nastanku tzv. redukcija, tj. naseobina u kojima se obavljala evangelizacija indijanskih plemena Guarani i drugih, omogućen je odgovarajući pristup poznavanju onovremenih procesa, uz ostalo i sociogeografskih, u prostoru južnoameričkoga geopolitičkog sraza dvaju katoličkih kolonijalnih imperija, španjolskog i portugalskog. U porječjima Parane, Paragvaja, Urugvaja s njihovim brojnim pritokama, u okviru većeg broja (više od četrdeset) misija na teritoriju današnje Argentine, Paragvaja, Bolivije i Brazila, između 1585. (1604.) i 1767. ostvarivani su suživot i društveno-gospodarsko uređenje potaknuti djelovanjem požrtvovnih isusovaca, među kojima se ističu i oni iz hrvatskoga prostora tadašnje Austrijske provincije Družbe Isusove, Ivan Krstitelj Marchesetti iz Rijeke i Nikola Plantić iz Zagreba, čija su pisma predmet ove knjige. Red kojem su pripadali zacrtao je stvaranje kršćanskog društva, ustrojstveno i gospodarski izvan utega tadašnjih europskih kasnofeudalnih odnosa, bližeg pravednim novozavjetnim učenjima o ravnopravnosti i vrijednosti svih ljudskih bića. Taj „jedinstveni socijalni eksperiment u povijesti čovječanstva“, koji je imao i svoje političko-geografsko naličje, premda je doživio mnoge poticaje, priznanja i podršku mnogih suvremenika, ugašen je, na štetu posebice brazilskih guaranskih misija. Tome su uzrok bila međudržavna i unutarcrkvena nesuglasja, agresivnost odmetnika i pojedinih kolonizatora te posebice objede i optužbe da misionari zlorabe zasnovane redukcije za svoje bogaćenje i širenje nekoga svojeg zamišljenog kraljevstva. Otuda i kasnije neosnovane i izmišljene reinterpretacije o Plantiću kao „paragvajskom kralju“, kao „komunističkom kralju“ i sl. Od 1585. do 1767. Družba je provela dvadesetpet istraživačkih pohoda, ostavivši o tome brojna pismena svjedočanstva. Epilog gotovo dvostoljetnih nastojanja isusovaca, u vrtlogu dinastičkih interesa i prekrajanja i u sukobu portugalskih i španjolskih geopolitičkih prisezanja, bio je, nažalost, porazan, posebice za stotine tisuća domorodaca koji su pristali na pokrštavanje i novi način života ostvaren kroz misionarske redukcije. Pojam redukcija (lat. reducere – natrag dovesti) ovdje označava misijska naselja, tzv. Paragvajske redukcije u koje su iz divljih krajeva i prašuma okupljani Indijanci da žive sigurni u organiziranoj kršćanskoj zajednici. Prostirale su se na području dugačkom više od 1000 km i širokom oko 300 km, površine više od 400 tisuća četvornih kilometara. Prva je bila Loreto (1609.), u pokrajini Guayara. Najsjevernija redukcija, San Ignacio del Norte, bila je na 16. usporednici, a najjužnija, Yapeyu, između 29. i 30. usporednice južne zemljopisne širine. U početku su bile izrazito ugrožene od neprijatelja kraljevske kuće i guvernera, raznih španjolskih upravitelja i veleposjednika, portugalskih trupa i posebice odmetnika, a kasnije su konsolidirane u tzv. Kršćansku Republiku Paragvaj koja je uživala visoku autonomiju unutar Španjolskog Kraljevstva. U vrijeme procvata redukcija, ustrojenih po načelu „zajednički posjed, zajednički rad, zajednički plodovi“ 30-ih i 40-ih godina 18. stoljeća živjelo je u njima i više od 140 000 osoba. Uređenje naseobina i zemljišnih imanja svakako je bitno utjecalo na stvaranje novoga oblika kulturnog krajobraza u divljim predjelima južnoameričkog kontinenta. U drugom dijelu knjige predstavljena su do sada neobjavljena pisma navedene dvojice hrvatskih isusovaca u izvorniku na španjolskom i u hrvatskom prijevodu, pisma iz njihove prepiske i druga pisma u kojima se spominje Ivan Marchesetti (Rijeka, 10. prosinca 1704. – Candelaria, Paragvaj, 5. veljače 1767.). Ivan Marchesetti umro je u Novom svijetu prije protjerivanja Družbe Isusove 1767. godine. U Argentinu je stigao 1734. i ondje, poslije priprema u Córdobi, od 1738. do smrti djelovao kao misionar i upravitelj u sedam misija. U Nuestra Señora de Fe uveo je plantažni uzgoj štitastih uši – košenila za proizvodnju grimiznih boja te priređivanje lijekova i začina te ustrojio samoobranu grada. Uspješno je pokrenuo proizvodnju i trgovinu poljoprivrednim kulturama u redukcijama (maté, duhan, trska, sukno i dr.). Nikola Plantić (Zagreb, 2. prosinca 1720. – Varaždin, 15. lipnja 1777.), koji je bio u Paragvaju, ali nije poslan u misije, nego je kao profesor filozofije i teologije boravio u Cordobi, vratio se u Hrvatsku gdje je i umro. Prije odlaska u Južnu Ameriku 1748. studirao je filozofiju u Zagrebu i Grazu, a teologiju u Trnavi te 1747. zaređen. Bio je i rektor isusovačkoga kolegija u Buenos Airesu te superior u Montevideu. Nakon izgona isusovaca na temelju patenta Karla III., vratio se 1768. u Zagreb. Od 1771. bio je rektor isusovačkoga kolegija u Varaždinu, gdje je ostao i nakon ukinuća reda 1773. Popraćena opsežnim bilješkama, pisma Marchesettija i Plantića subraći pohranjena u argentinskom državnom arhivu, svjedoče o misijama, tegobama, gospodarskom i društvenom ustroju, svakodnevnom životu, dvojbama i borbama misionara, kolonizatora i domorodačkih plemena. Prepisku je pronašao pok. Milan Blažeković te ju je predao 1992. godine drugom autoru knjige dr. Koradeu. Ova pisma, kao izvorna svjedočanstva, važna su potka u izučavanju povijesno-zemljopisnih okolnosti tristogodišnjega kolonijalnog razdoblja i nastanka južnoameričkih društava. Autori su ih popratili znanstvenim studioznim razmatranjima o životu i radu dvojice misionara te njihovu utjecaju na subraću redovnike, druge suvremenike i naraštaje koji su slijedili. Posebno je obrađena i legenda o kralju Nikoli, tj. intriga o Plantiću kao kralju paragvajskih Indijanaca, izmišljena i proširena za potrebe pristalica sramotno rigidne reakcije na jednu humanu, gospodarski uspješnu misionarsku stečevinu i koliko je bilo moguće, ostvarenje pravednog suživota domorodaca i kolonizatora. Svakoga geografa, kao i brojne druge čitatelje, zanimat će ovo štivo kao dokumentacija i svjedočanstvo jednog vremena i geopolitičkih zbivanja unutar kojih je, unatoč brojnim poteškoćama, ostvarena jedna od najhumanijih do sada poznatih ljudskih zajednica. Kada su godine 1750. Španjolska i Portugal provele bestidnu trgovinu s gradovima-misijama zamjenom sedam redukcija na istočnoj obali Urugvaja za bogatu koloniju San Sacramento na ušću rijeke La Plate, u mjesec dana moralo se iseliti 30 tisuća ljudi sa svom pokretnom imovinom iz sedam misijskih župa. Guarani su morali prepustiti sav svoj 150-godišnji trud svojim neprijateljima. Brojni prosvjedi civilnih i crkvenih vlasti u Americi i u Španjolskoj nisu, nažalost, bili od pomoći. Unatoč kasnijem povratu na prijašnje stanje, protjerivanjem isusovačkog reda u Portugalu, ubrzo i u Španjolskoj, te geopolitičkim previranjima u 19. stoljeću, baština prosvjetiteljskih i vjerskih misija ubrzano se gasila. Ipak, ostale su brojne potvrde, uz ostalo i pisma naših redovnika, veličanstvenog postignuća jednoga crkvenog reda, doprinosa općem boljitku svijeta. Isusovci su svojim redukcijama u Paragvaju ispisali zasigurno jednu od najljepših stranica socijalne povijesti kao i povijesnog zemljopisa na karti svijeta. Knjiga je izašla u izdanju Matice hrvatske, kao prva knjiga u sklopu edicije Biblioteka Historia. Glavna urednica je Romana Horvat, a recenzenti su dr. sc. Marino Manin iz Instituta za migracije i narodnosti u Zagrebu i dr. sc. Damir Zorić, etnolog i povjesničar iz Matice hrvatske. Knjiga ima dvjesto četrdeset šest stranica s osamnaest slika (dvanaest u bojama), bibliografijom i kazalom osobnih imena. Kao što je s uspjehom i suosjećanjem za Guaranske redukcije svojevremeno prihvaćen filmski oskarovac Misija na ovu temu, tako i ova knjiga ne ostavlja ravnodušnima sve one koji teže pravednijim i humanijim odnosima među ljudskim zajednicama.

Abstract BACKGROUND Endocrine therapies (ETs) that target estrogen receptor (ER) activity and/or estrogen synthesis are the mainstay of ER+ breast cancer (BC) treatment. Despite best management, ≤20% of patients (pts) with ER+/HER2– early BC (eBC) develop resistance (in some cases due to acquisition of tumor mutations in ESR1 that can drive estrogen-independent transcription and proliferation) and still have high recurrence rates on standard ETs. New treatment alternatives for ER+/HER2– eBC are needed to reduce risk of recurrence and improve survival, tolerability, quality of life, and adherence. Giredestrant, a highly potent, nonsteroidal oral selective ER antagonist and degrader (SERD), achieves robust ER occupancy and is active against tumors that retain ER-sensitivity or have ESR1 mutation(s). It has been demonstrated to be more potent in vitro and achieves higher ER occupancy in vivo than fulvestrant, the only currently approved SERD. Early-phase clinical studies have demonstrated that single-agent giredestrant (30 mg daily) has promising clinical and pharmacodynamic activity and is well tolerated in the ER+/HER2– eBC and metastatic BC settings. TRIAL DESIGN This is a phase III, global, randomized, open-label, multicenter study evaluating efficacy and safety of adjuvant giredestrant vs physician’s choice of adjuvant ET (PCET) in pts with medium- and high-risk stage I–III histologically confirmed ER+/HER2– eBC. Pts are randomized 1:1 to oral 30 mg daily giredestrant or PCET (tamoxifen, anastrozole, letrozole, or exemestane, given according to prescribing information). Stratification factors are risk (medium vs high, based on anatomic [tumor size, nodal status] and biologic features [grade, Ki67, gene signatures if available]); geographic region (US/Canada/Western Europe vs Asia-Pacific vs rest of the world); prior chemotherapy (no vs yes); and menopausal status (pre-/perimenopausal vs postmenopausal). Beginning on Day 1 of Cycle 1, pts will be treated with giredestrant or PCET for ≥5 years. Continuing PCET after 5 years is at discretion of the investigator and per local standard of care. ELIGIBILITY Female/male pts with medium-/high-risk stage I–III ER+/HER2– eBC; prior curative surgery; completion of (neo)adjuvant chemotherapy (if administered) and/or surgery &lt; 12 months prior to enrollment; no prior ET (≤4 weeks of [neo]adjuvant ET is allowed). For men and pre-/perimenopausal women, a luteinizing hormone-releasing hormone agonist will be given per local prescribing information (mandatory for pts in the giredestrant arm). AIMS Primary endpoint: Invasive disease-free survival (IDFS). Secondary endpoints: Overall survival; IDFS (STEEP definition, including second non-primary BC); disease-free survival; distant recurrence-free survival; locoregional recurrence-free interval; safety; pharmacokinetics; pt-reported outcomes. In addition, this study aims to improve health equity in research and expand clinical trial access. The study will also use/develop digital healthcare solutions, which will enable better understanding of pts’ needs and their adherence to ET. STATISTICAL METHODS The primary endpoint analysis will use a stratified log-rank test at an overall 0.05 significance level (two-sided). An interim analysis and a futility analysis are planned, and an independent data monitoring committee will be in place. ACCRUAL 1018/4100 pts have been recruited globally. CONTACT INFORMATION For more information or to refer a patient, email global.rochegenentechtrials@roche.com or call 1-888-662-6728 (USA only). Clinicaltrials.gov number NCT04961996. AB, PS and CG contributed equally. This abstract was originally presented at SABCS 2021 (OT2-11-09). a&gt;Disclosure(s): Peter Schmid, MD, PhD: Astellas Pharma: Contracted Research (Ongoing); AstraZeneca: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Honoraria (Ongoing); Bayer: Consulting Fees (e.g., advisory boards) (Ongoing), Honoraria (Ongoing); Boehringer Ingelheim: Consulting Fees (e.g., advisory boards) (Ongoing), Honoraria (Ongoing); Celgene: Consulting Fees (e.g., advisory boards) (Ongoing); Eisai: Consulting Fees (e.g., advisory boards) (Ongoing); F. Hoffmann-La Roche Ltd.: Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing); Genentech: Contracted Research (Ongoing); Medivation Inc.: Contracted Research (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing), Honoraria (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Honoraria (Ongoing); OncoGenex: Contracted Research (Ongoing); Pfizer: Consulting Fees (e.g., advisory boards) (Ongoing), Honoraria (Ongoing); Puma Biotechnology: Consulting Fees (e.g., advisory boards) (Ongoing), Honoraria (Ongoing); Roche: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Honoraria (Ongoing) Charles E. Geyer Jr, MD, FACP: Abbvie: Contracted Research (Terminated, July 1, 2022), Writing assistance (Terminated, July 1, 2022); AstraZeneca: Contracted Research (Ongoing), Writing assistance (Ongoing); Daiichi/Sankyo: Contracted Research (Ongoing); Exact Sciences: Consulting Fees (e.g., advisory boards) (Ongoing); F. Hoffman-La Roche Ltd: Contracted Research (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche) (Ongoing); Genentech: Contracted Research (Ongoing), Writing assistance (Ongoing) Nadia Harbeck, MD, PhD: Amgen: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); AstraZeneca: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Daiichi Sankyo: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Eli Lilly: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Exact Sciences: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); MSD: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Pfizer: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Pierre Fabre: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Roche: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing); Sandoz: Consulting Fees (e.g., advisory boards) (Ongoing); Seagen: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); WSG: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing) Mothaffar Rimawi, MD: Daiichi Sankyo: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); F. Hoffmann-La Roche Ltd.: Contracted Research (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing); Genentech: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Macrogenics: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Pfizer: Contracted Research (Ongoing); Seattle Genetics: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing) Sara Hurvitz, MD, FACP: Ambrx: Contracted Research (Ongoing); Amgen: Contracted Research (Ongoing); Arvinas: Contracted Research (Ongoing); Astra Zeneca: Contracted Research (Ongoing); Bayer: Contracted Research (Ongoing); Cytomx: Contracted Research (Ongoing); Daiichi-Sankyo: Contracted Research (Ongoing); Dignitana: Contracted Research (Ongoing); Eli Lilly: Contracted Research (Ongoing); Genentech/Roche: Contracted Research (Ongoing); Gilead: Contracted Research (Ongoing); GSK: Contracted Research (Ongoing); Ideal Implant: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Immunomedics: Contracted Research (Ongoing); Macrogenics: Contracted Research (Ongoing); Novartis: Contracted Research (Ongoing); OBI Pharma: Contracted Research (Ongoing); Orinove: Contracted Research (Ongoing); Pfizer: Contracted Research (Ongoing); Phoenix Molecular Designs, Ltd.: Contracted Research (Ongoing); Pieris: Contracted Research (Ongoing); PUMA: Contracted Research (Ongoing); Radius: Contracted Research (Ongoing); Sanofi: Contracted Research (Ongoing); Seattle Genetics/Seagen: Contracted Research (Ongoing); Zymeworks: Contracted Research (Ongoing) Miguel Martín, MD, PhD: AstraZeneca: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Daiichi Sankyo: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); F. Hoffmann-La Roche: Third-party writing assistance for this abstract, furnished by Eleanor Porteous, MSc, of Health Interactions, was provided by Roche (Ongoing); Genentech/Roche: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing); Gilead: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Lilly/ImClone: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing), Honoraria (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing), Honoraria (Ongoing); Pfizer: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing), Honoraria (Ongoing); Pierre Fabre: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing), Honoraria (Ongoing); Seagen: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing), Honoraria (Ongoing) Sherene Loi, MBBS (Hons), PhD, FRACP, FAHMS, GAICD: Aduro Biotech, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Akamara Therapeutics: Uncompensated scientific advisory board member (Ongoing); AstraZeneca: Consulting Fees (e.g., advisory boards) (Ongoing), Uncompensated consultant (Ongoing); BMS: Uncompensated consultant (Ongoing); Breast Cancer Research Foundation, New York: Supported by the Breast Cancer Research Foundation, New York (Ongoing); G1 Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); GlaxoSmithKline: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Uncompensated consultant (Ongoing); National Breast Cancer Foundation of Australia Endowed Chair: Supported by the National Breast Cancer Foundation of Australia Endowed Chair (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing), Uncompensated consultant (Ongoing); Roche-Genentech: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing), Uncompensated consultant (Ongoing); Seattle Genetics: Uncompensated consultant (Ongoing); Silverback Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing) Shigehira Saji, MD, PhD: Astra Zeneca: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Bayer: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Boerhringer-ingelheim: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Breast International Group: Executive board member (Ongoing); Chugai: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Daiichi Sankyo: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Eisai: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Eli Lilly: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); F. Hoffmann-La Roche Ltd.: Contracted Research (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing); Japan Breast Cancer Research Group: Executive board member (Ongoing); Japanese Breast Cancer Society: Executive board member (Ongoing); Japanese Society of Medical Oncology: Executive board member (Ongoing); Kyowa Kirin: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); MSD: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Nihonkayaku: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Novartis: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Ono: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Pfizer: Consulting Fees (e.g., advisory boards) (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Taiho: Contracted Research (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); Takeda: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing) Kyung Hae Jung, MD, MS, PhD: AstraZeneca: Consulting Fees (e.g., advisory boards) (Ongoing); Celgene: Consulting Fees (e.g., advisory boards) (Ongoing); Daiichi-Sankyo: Consulting Fees (e.g., advisory boards) (Ongoing); Eisai: Consulting Fees (e.g., advisory boards) (Ongoing); Everest Medicine: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing); MSD: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Pfizer: Consulting Fees (e.g., advisory boards) (Ongoing); Roche: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing); Takeda: Consulting Fees (e.g., advisory boards) (Ongoing) Gustavo Werutsky, MD, PhD: AstraZeneca: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Honoraria (Ongoing); Bayer: Contracted Research (Ongoing); Beigene: Contracted Research (Ongoing); Daiichi Sankyo: Consulting Fees (e.g., advisory boards) (Ongoing); Genentech/Roche: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) (Ongoing); GSK: Contracted Research (Ongoing); Lilly: Contracted Research (Ongoing), Honoraria (Ongoing); MSD: Honoraria (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Honoraria (Ongoing); Pfizer: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Honoraria (Ongoing); Sanofi: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing); Seattle Genetics: Contracted Research (Ongoing) Daniil L. Stroyakovsky, MD: Roche: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing) Vanesa López-Valverde, PharmD, PhD: F. Hoffmann-La Roche Ltd.: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Salary (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing) Michael Davis, PsyD: F. Hoffmann-La Roche Ltd.: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing); Genentech, Inc.: Salary (Ongoing) Tanja Badovinac Crnjevic, MD, PhD: F. Hoffmann-La Roche Ltd.: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Salary (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing) Pablo D. Perez-Moreno, MD: F. Hoffmann-La Roche Ltd.: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Third-party writing assistance for this abstract, furnished by Sunaina Indermun, BPharm, PhD, of Health Interactions, was provided by Roche (Ongoing); Genentech, Inc.: Salary (Ongoing) Aditya Bardia, MD, MPH: AstraZeneca: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing); BioTheranostics: Consulting Fees (e.g., advisory boards) (Ongoing); Daiichi Sankyo: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing); Eli Lilly: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing); Foundation Medicine: Consulting Fees (e.g., advisory boards) (Ongoing); Genentech/Roche: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing); Immunomedics/Gilead: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing); Pfizer: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing); Phillips: Consulting Fees (e.g., advisory boards) (Ongoing); Radius Health: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing); Sanofi: Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing) &lt;/a&gt; Citation Format: Peter Schmid, Charles E. Geyer Jr, Nadia Harbeck, Mothaffar Rimawi, Sara Hurvitz, Miguel Martín, Sherene Loi, Shigehira Saji, Kyung Hae Jung, Gustavo Werutsky, Daniil L. Stroyakovsky, Vanesa López-Valverde, Michael Davis, Tanja Badovinac Crnjevic, Pablo D. Perez-Moreno, Aditya Bardia. lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT2-03-02.

El libro es producto de un trabajo de recopilación y transcripción de archivos magnetofónicos y fue revisado por el profesor Darío Mesa Chica. Su contenido se desagrega en seis capítulos así: Contexto social y político colombiano del siglo XIX; El pensamiento de Caro sobre la moneda; Fuentes y rasgos característicos de la personalidad intelectual de Caro; Caro pensador y hombre de acción; Pensamiento político de Miguel Antonio Caro; Anotaciones complementarias a las exposiciones de varios participantes, bibliografía e índice de materias. Las seis lecciones que presenta el texto tienen, para los estudiosos de las ciencias sociales en América Latina, un conjunto de valores, que deben ser destacados.

El presente trabajo intenta reflexionar y proponer el siglo XIX como un sistema de representación, en donde la actividad retórica lideraba el escenario político, el histórico y el social. Por tal motivo, estos sistemas enunciativos exponen, de manera clara y radical, una suerte de regímenes de representación, que evidenciaban, no sólo a través de la praxis del discurso sino también de su estudio y normatización, enfrentamientos en donde el sistema de jerarquización de la palabra, jugaba un papel fundamental de estudio y comprensión de la lengua como elemento de poder e identidad.

<div class="page" title="Page 2"><div class="layoutArea"><div class="column"><div class="page" title="Page 2"><div class="layoutArea"><div class="column"><p><span>Este artículo propone una interpretación del modo en que la doctrina de Miguel Antonio Caro, en particular sus concepciones de historia, progreso y orden, dieron lugar a un pensamiento sobre la lengua que se configura entre dos tendencias: la antigua y la nueva, la clásica y la moderna. Respecto a esta dinámica oscilante se presenta un análisis de la política de la lengua, implementada por algunos miembros de la Academia Colombiana de la Lengua, teniendo como principal referente teórico el estudio de Michel de Certeau, Dominique Julia y Jacques Revel, acerca de un saber lingüístico definitivo para la comprensión de la lengua nacional y el tratamiento de los </span><span>patois </span><span>—dialectos- vigentes en una nación. El argumento central consiste en que la tensión que resulta del acogimiento de una filosofía tradi-cionalista y la adopción de elementos de un saber científico sobre la lengua, permitió que un grupo específico de académicos pensara una forma particular de avanzar en la civilización y consolidación de un Estado-Nación moderno. </span></p></div></div></div></div></div></div>